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Abstract
Low birth weight (LBW), and maternal Western Diet (WD) consumption have both been
independently implicated to increase the risk of developing cardiovascular diseases (CVDs) in
later life. These fetal programmed risks are also believed to exacerbate the effects of a postnatal
WD pattern, therefore resulting in the development of pre-clinical markers of CVDs, such as
insulin resistance (IR), coronary circulation disruptions. This thesis aimed to elucidate the roles
of sub-optimal in utero growth through placental insufficiency, or chronic maternal WD
consumption, and postnatal WD consumption on the long-term programming of CVDs in a
guinea pig model. Early pre-clinical markers of CVD development including reduced coronary
flow, left ventricular hypertrophy, and fibrosis were observed in the young LBW offspring.
Postnatal consumption of WD was itself strongly associated with the early development of
cardiac IR. Collectively these findings suggests that prenatal insults combined with a postnatal
dietary insult, can lead to an increased risk of developing CVDs.
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Chapter 1

1

Literature Review

2

1.1

Cardiovascular Diseases

The burdens of chronic non-communicable diseases (NCDs) are becoming more
apparent in today’s society. According to the World Health Organization, NCDs are
responsible for approximately nine million of all premature deaths before the age of 60. In
particular, low and middle income countries are especially susceptible to NCDs, where
they make up 90% of all NCD related premature deaths. Of the many types of NCDs,
cardiovascular disease (CVD) distinguishes itself ahead of cancers, respiratory diseases
and diabetes as the leading cause of NCD related deaths. In 2008 alone, approximately 17.3
million people worldwide died from CVDs, with a mortality rate of 17%1,2. Unfortunately,
this figure is expected to rise in the future, with an estimated growth to 24% of all
mortalities1,2.
These alarming trends can be attributed to the increasing prevalence of risk factors
for CVDs in both developing and developed countries. These risk factors include tobacco
use, physical inactivity, obesity, and dietary choices such as the consumption of foods high
in sugars and/or saturated fatty acids3–5. In addition, prenatal complications and the
associated low birth weight (LBW) are also recognized by the United Nations as factors
which predispose an individual to the development of heart diseases and obesity in
adulthood6. Collectively these risk factors contribute to the development of different types
of CVDs, including coronary artery disease, congenital heart diseases, hypertension, and
cardiomyopathy. In particular, cardiomyopathy, with its asymptomatic nature, and ties to
both prenatal and postnatal risk factors, presents a substantial risk to our society, and is
therefore an important area of focus7,8.

3

1.1.1

Cardiomyopathy

Cardiomyopathy is defined as the disease of the myocardium associated with
mechanical or electrical dysfunction, leading to cardiovascular death and progressive heart
failure8,9. In a 2010 study by the American Heart Association, cardiomyopathy affects
approximately 2.6% of the US population with a mortality rate of 56.3%, costing the health
care system approximately $39.2 billion10. Patients with cardiomyopathy experience
shortness of breath, fatigue, and chest pain; however, many remain asymptomatic7,8.
Cardiomyopathy can be categorized into two major groups: primary or secondary.
Primary cardiomyopathies are solely confined to the heart, while secondary
cardiomyopathies result from conditions which affect other parts of the body such as
Gaucher disease and diabetes11. A common type of primary cardiomyopathy is
hypertrophic cardiomyopathy, where the enlargement of cardiomyocytes results in the
asymmetric thickening of the left ventricle, increase in left ventricular stiffness, and
ischemia9,12. The etiology of hypertrophic cardiomyopathy is familial or genetic, but can
also develop over time from chronic high blood pressure9,12. Clinically, hypertrophic
cardiomyopathy is characterized by a hypertrophied myocardium and an un-dilated left
ventricular chamber. In comparison, another type of the disease is dilated cardiomyopathy,
where the enlargement of cardiomyocytes results in the stretching and thinning of the left
ventricle and a dilated ventricular chamber13. Dilated cardiomyopathy is non-ischemic in
nature, and although categorized as a primary type of the disease, it is idiopathic, with
probable causes such as infections, genetic factors, diabetes, and heart attack7,9. While both
hypertrophic and dilated cardiomyopathy have different causes and pathophysiology, they
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do, however, share a common feature, which is cardiomyocyte enlargement. This process,
otherwise known as cardiac hypertrophy, is an important risk factor in myocardial
infarction, sudden death, and nearly all forms of heart failure including cardiomyopathy14.

1.1.2

Cardiac Hypertrophy

The heart is composed of cardiomyocytes (muscle cells) and non-myocytes such as
fibroblasts and endothelial cells15. As a post-mitotic organ, cardiomyocyte proliferation
normally occurs in utero. Shortly after birth, cardiomyocytes lose the ability to proliferate,
and as a result, postnatal cardiac growth is dependent on cardiomyocyte enlargement and
the proliferation of non-myocytes16,17. Often, in response to chronic increases in functional
load, ventricular wall stress, and load which the blood is ejected against, intrinsic mechanosensing mechanisms which signals the enlargement of heart mass are activated. This
cardiomyocyte enlargement is defined as cardiac hypertrophy, and is a major component
of cardiac remodelling18–20.
Hypertrophic growth can be classified as concentric or eccentric depending on the
change in cardiomyocyte shape. In concentric hypertrophy, the increase in cardiac myocyte
width in response to pressure overload results in the thickening of the ventricular wall and
minor reductions in chamber volume. In comparison, eccentric growth is the increase in
cardiomyocyte length in response to volume overload, which results in increased chamber
volume with decreased or unaltered wall thickness21,22. Cardiac hypertrophy can be further
classified as either physiological or pathological hypertrophy. Physiological hypertrophy
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is exercise induced, with normal cardiac morphology, and is typically reversible23. In
contrast, pathological growth occurs as a result of increased load in a disease setting such
as myocardial infarction, coronary artery disease, and cardiomyopathy14. Depending on the
nature of the disease, such as pressure or volume overload, pathological hypertrophy can
occur under concentric or eccentric growth promoting conditions. In addition to increased
heart and cardiomyocyte size, pathological hypertrophy is also accompanied by
cardiomyocyte death, and fibrosis14,24,25. More worryingly, over 50% of all hypertrophyrelated deaths in adults are sudden, with minimal or no prior symptoms26. Given the high
prevalence of hypertrophy related cardiac dysfunctions, and the sudden nature of
hypertrophy-related deaths27,28, it is important to examine possible markers of CVD
development for diagnostic and intervention purposes.

1.1.3

Preclinical Metabolic Markers of CVD Development

The main source of energy generation in the heart is from fatty acid oxidation
(~70% of ATP production), while glucose metabolism accounts for approximately 30% of
ATP production. In order to maintain a steady supply of energy, the heart is also capable
of switching between energy sources in order to adapt to different workloads, or fuel
molecules29. Interestingly, in the early stages of pathological hypertrophy, a decrease in
fatty oxidation and increase in glucose metabolism is observed30–32. This switch towards
glucose metabolism often occurs during the early stages of CVDs, and mirrors the
metabolic patterns of a fetal or newborn heart33. However, like the fetal heart, glucose

6

transport is mainly handled by the insulin independent glucose transporter 1 (GLUT1)
rather than the insulin dependent GLUT4. This results in a reduction in GLUT4/GLUT1
ratio, and insulin dependent glucose uptake34,35. While this mechanism is initially
protective against further disease progression (e.g. increasing blood pressure, and reducing
coronary blood flow). However, ATP production falls as glucose uptake and metabolism
is progressively reduced with the emergence of insulin resistance (IR), a key pre-clinical
marker associated with developing CVD36–38.
A canine model of advanced dilated cardiomyopathy demonstrated that myocardial
IR and increases in fatty acid concentration occurred in parallel with CVD disease
progression39. Additionally, in severe cases of cardiomyopathy, ATP levels are decreased
along with the impairment of cardiac insulin signaling pathways39. It can be inferred that
IR is associated with decreased ATP stores during a period of crucial dependence on
glucose uptake and utilization39. Other studies have also suggested that the development of
cardiac IR is in fact a protective mechanism against heart failure, particularly in the
presence of a high-saturated fat diet40. For example, insulin resistant rats with mild to
moderate heart failure that were fed a high fat diet exhibited decreased glucose utilization,
but preserved contractile function40. The reduction in glucose metabolism was likely
compensated by increased fatty oxidation41, and that the insulin resistant animals were
therefore forced to use fatty acid oxidation as a means for energy production. This in turn
would direct fatty acids to productive pathways such as β-oxidation and triglyceride
synthesis, which therefore reduce the formation of lipotoxic intermediates such as
diacylglycerol (DAG) and ceramides to preserve cardiac function40,42. Nonetheless, the
implications of cardiac IR are still poorly defined. However, it is apparent that its
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development, along with alterations in glucose uptake is often in concert with CVDs such
as cardiomyopathy.
Under normal circumstances, cardiac glucose uptake is mediated by insulin
dependent glucose transporters GLUT4 and insulin independent GLUT1, which accounts
for approximately 60% and 40% of all glucose uptake in the heart respectively43. Both
transporters are widely distributed in fetal tissues. However, while GLUT1 is membrane
bound and insulin independent, GLUT4 activity requires its translocation to the membrane,
a process mediated by the insulin signaling pathway44. Interestingly, although GLUT1
activity is classically non-insulin dependent, recent evidence shows that insulin may play
a minor role in GLUT1 translocation during diabetic stages45. In inducing GLUT4
transporter proteins to the cell membrane, insulin first binds to insulin receptor on the cell
surface, which leads to the phosphorylation of insulin receptor, tyrosine phosphorylation
of insulin receptor substrate (IRS), the activation PI3-kinase, and phosphorylation of AKT
(protein kinase B) at Threonine 308 and Serine 473. Activated AKT and PI 3-kinase is then
involved in promoting the translocation of GLUT4 from intracellular storage to the plasma
membrane46. This signaling pathway, particularly Phosphoinositide 3- Kinase (PI3-K)
activation, is necessary for insulin stimulated glucose uptake. However, during states of IR
when the action of insulin is impaired, there appears to be a decrease in insulin associated
stimulation of IRS and PI3-kinase, and activation of AKT. This ultimately results in a
decrease of GLUT4 translocation, and a reduction in glucose uptake and metabolism47.
Taken together, given that this state of myocardial IR typically precedes the onset of severe
CVDs, early detection of changes in myocardial insulin sensitivity and glucose uptake may
be an effective early predictor CVD48.
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1.1.4

Coronary Blood Flow as Markers of Cardiomyopathy Development

With the increasing severity of myocardial IR and CVD development, comes
progressive injury to the coronary circulation37. For example, in the previously mentioned
canine model of advanced dilated cardiomyopathy, progressive hemodynamic impairment
in coronary blood flow also occurred in parallel with myocardial IR and increasing severity
of cardiovascular complications39. Symptoms of coronary vascular dysfunction are often
found in patients with cardiomyopathy. A substantial body of evidence also suggests that
reductions in coronary blood flow is a key marker in the development of
cardiomyopathy49,50. For instance, coronary blood flow, as determined by Positron
Emission Tomography (PET), was particularly blunted in patients later identified with
severe heart failure or death51. Similarly, patients with dilated cardiomyopathy also
displayed reduced coronary blood flow in conjunction with cardiac enlargement52. It is
clear from these studies that impairments in coronary flow underlie the development of
many CVDs. Furthermore, an Italian study of patients with various degrees of left
ventricular dysfunction suggests that coronary blood flow reduction is a stronger predictor
of risk of death and development of heart failure than other common clinical prognoses
such as echocardiography53. The effects of IR on coronary circulation remains to be
elucidated. However it is clear that progressively worsening coronary circulation function
occurs with increasing severity of IR. A possible underlying factor may be the abnormal
insulin mediated, nitric oxide dependent vasodilation during IR54. Nevertheless, it is
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evident that coronary blood flow is a reliable predictor of systolic dysfunction and
developing heart failure associated with cardiac remodeling processes.

1.1.5

Cardiac Remodeling Consequences

Pathological hypertrophy is characterized in the later disease stages by
cardiomyocyte enlargement, and the onset of fibrosis, resulting in the thickening and
stiffening of the ventricular wall52. These cardiac remodeling processes are considered a
crucial component leading to systolic dysfunction, and impediment of contractility.
Furthermore, there are compelling evidence which suggests that the reduction in resting
coronary flow may be associated with the expansion of extra-cellular space and ventricular
dilation52. Specifically, the onset of fibrosis from an excessive expression of collagen is
associated with diminished capillary density and myocardial ischemia55. Myocardial
capillaries are known to be the primary determinant of coronary microvascular flow.
Reductions in capillary density may result in higher capillary resistance, which requires
arteriole and vein vasodilatation to maintain blood flow56. This has been observed in
patients with dilated cardiomyopathy where, despite the appearance of normal coronary
arteries, reduction in myocardial capillary density was strongly associated with reduced
coronary blood flow and heart failure57. In addition, the accumulation of collagen in the
cardiac interstitium (interstitial fibrosis) in cases of heart failure may also lead to a decrease
in capillary density, subjecting cardiac myocytes to a state of hypoxia58.
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The development of CVDs such as cardiomyopathy are characterized by cardiac
remodeling processes such as hypertrophy and fibrosis, as well as alterations in cardiac
glucose metabolism and insulin sensitivity. As these factors accumulate, they lead to the
development of systolic dysfunction, heart failure, and ultimately, death. Given the clear
metabolic and functional consequences of CVDs such as cardiomyopathy, early detection
of these markers prior to the onset of severe disease phenotypes is crucial for interventional
therapies. Traditionally, risk factors for the development of CVDs are primarily postnatal.
However, emerging evidence suggests that the origin of these chronic adult diseases may
be as early as during the in utero period59. Therefore, a key question in this thesis is whether
prenatal insults, combined with the traditional postnatal factors for CVDs, can lead to the
early development of CVDs.
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1.2 Developmental Origins of Health and Disease

1.2.1

Intrauterine Growth Restriction and Low Birth Weight

According to the World Health Organization, the worldwide prevalence of low
birth weight babies (LBW; <2500g) is at approximately 15.5%60. Specifically, the Canadawide occurrence of LBW is lower at 5.9%. LBW infants are often a consequence of suboptimal in utero environments, such as in cases of intrauterine growth restriction (IUGR).
Clinically, growth restriction can be defined as birth weight falling below the 10th
percentile for a specific sex of gestational age60. This inability of the fetus to reach its
expected growth potential may impart significant risks in perinatal morbidity and
mortality61,62. Interestingly, studies have demonstrated that offspring beyond the arbitrary
birthweight cut-off in the clinical IUGR categorization can also be exposed to an adverse
in utero environment, and display the same complications in adulthood63. This is
exemplified by reports of offspring above the clinical birthweight cut-off displaying
markers of poor in utero growth, such as thinness at birth, and pattern of rapid postnatal
catch-up growth64. Therefore, a potentially larger number of adversely grown offspring
may be at risk for later life complications such CVDs than what the traditional measures
suggest. Given the increasing risk of developing metabolic diseases in later life, and the
potentially higher cost of treating later life disease as opposed to early invention programs,
it is imperative that we understand the etiology, and underlying mechanisms of growth
restriction and fetal programming59,65.

12

A reliable diagnosis of IUGR infants is crucial to understanding the effects of
growth restriction on the development of complications in later life. Traditionally, the use
of Ponderal index, the ratio of weight/(height3), is an excellent assessment of neonatal
growth retardation, and is positively correlated with fetal nutritional status at term66,67.
Furthermore, IUGR can be classified under two distinct patterns of growth abnormality:
symmetrical, or asymmetrical, therefore, careful attention to body and growth relationships
are essential in understanding the in utero growth regime68. Symmetrical IUGR, which is
the proportionate decrease of fetal abdomen and head growth, results in a normal Ponderal
index. It is generally associated with early fetal insults during the first or second
trimester69,70. Asymmetrical IUGR in comparison, refers to the disproportionate decrease
in fetal abdomen and head growth, known as the “brain sparing” effect, and is the most
common form of IUGR (~70%). This is attributed to the ability of the fetus to adapt, and
redistribute its cardiac output to essential circulations such as cerebral, and coronary
circulation in response to insults during the last trimester71,72.
The causes of IUGR are multifactorial and can be summarized into three major
scenarios: inadequate maternal supply of oxygen and nutrients, inability of fetus to fully
utilize the supply of oxygen and nutrients, and abnormal placental function

71

. Maternal

complications such as hypertension, diabetes, and under-nutrition accounts for
approximately 25-30% of IUGR cases73. For example, maternal hypoxia in conditions such
as pulmonary diseases and hypertension are often associated with growth restricted
fetuses74,75. To a lesser extent, fetal disorders, including genetic diseases, and congenital
malformations are also associated with the development of IUGR76. According to the
Metropolitan Atlanta Congenital Defects Program, approximately 38% of chromosomally
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abnormal infants displayed signs of IUGR77. Lastly, because fetal growth and development
is largely dependent on oxygen delivery. It can therefore be inferred that normal placental
development is integral for the transport of oxygen and nutrient to the fetus, and
maintaining a healthy pregnancy. Furthermore, smaller placentas, and reduced placenta to
fetal weight ratio are associated with growth restricted infants78. A common complication
which plagues the prevalence of growth retardation is placental insufficiency.

1.2.2

Placental Insufficiency

Placental insufficiency (PI) is the inability of the placenta to provide the required
transport of oxygen and nutrients to fully support the developing fetus. PI is known to be
responsible for the majority of IUGR cases, and a critical component is fetal hypoxia79,80.
Although the mechanisms underlining the development of PI are idiopathic, these
idiopathic pregnancies and fetal hypoxia occur due to natural placental development
failures81,82. Normally, as gestation advances, the growing vascular network and decrease
in vascular resistance, results in the increase in both uterine and umbilical blood flow83,84.
However, as PI develops, vascular growth is impaired, and vascular resistance in umbilical
and uterine arteries increases, resulting in a 2.5 fold reduction in absolute blood flow85–87.
Studies have also postulated that abnormal fetal trophoblast invasion of maternal decidua
is associated with an impaired transformation of spiral arteries into low resistance vessels,
thus reducing utero-placental blood flow88. It is thus evident that when the placenta fails to
supply the fetus with adequate oxygen and nutrients, fetal growth will fall from its genetic
trajectory and result in growth restriction89

14

1.2.3

Fetal Programming and Catchup Growth

The theory of fetal programming suggests that insults during gestation may impair
the growth of the fetus, and can lead to the development of chronic diseases in later life59.
The association between growth in utero and adult disease development was first
developed by Forsdahl in the 1970s. Using official statistical data in Norway, Forsdahl
reported that poor environments in childhood and adolescence followed by periods of
prosperity was correlated with the risk of coronary heart disease90. Moving forward to the
1980s, Barker and colleagues also reported a strong correlation between LBW and later
life development of coronary heart diseases in England and Wales91. In addition, using the
official Hertfordshire medical records from 1911-1930, Barker also reported that LBW was
associated with the development of IR at a mature age of 6492. These studies eventually
spawned the Forsdahl-Barker hypothesis, then later, the Developmental Origins of Health
and Disease hypothesis, which recognized that development of chronic metabolic diseases
in later life are a result of programming mechanisms during critical periods of in utero life.
Further support for the idea that the prenatal period represents a critical period in
later life disease development is highlighted by the study of the Dutch hunger winter at the
height of the Second World War. As a result of the German occupation and blockade,
civilians in the Netherlands experienced a famine during the winter of 1944. Individuals
born during this period with maternal caloric restrictions displayed a 300 gram decrease in
average birth weight, and in later life, an impaired glucose tolerance compared to those
born prior to the incident93,94.

15

In response to inadequate in utero environments, the fetus may be programmed for
a nutritionally poor postnatal environment95,96. However in setting this phenotype, a
mismatch of postnatal environment can also predispose the individual to later life
development of chronic diseases. This can be highlighted by examining the events of the
Leningrad siege during the Second World War. These studies demonstrated that the
glucose tolerance of individuals born during the siege (exposed to the famine) were not
different from the individuals born after the siege97. This observation may seem at odds
with previous example of the Dutch hunger winter, however this discrepancy can be
explained by a major difference between the two events. While the Dutch hunger winter
lasted for 6 months, the Leningrad siege lasted for 28 months. Victims from the Leningrad
siege were therefore born into the famine and experienced a low nutrient diet longer than
those of the Dutch hunger winter98. Thus, it can be inferred that unlike their counterparts
in Leningrad, infants of the Dutch hunger experienced a mismatched postnatal environment
of high nutrient intake, which resulted in the programmed IR in adulthood. These studies
also highlights the postnatal period as another critical period in the development of diseases
in later life. Therefore warranting our attention to the concept of “catch-up growth”.
A postnatal “catch-up growth” describes the accelerated postnatal growth profile
which compensates for restricted growth during prenatal life, and is usually associated with
asymmetrical growth restricton69. However many studies have associated this accelerated
growth trajectory with the development of diseases in adulthood. For example, similar to
the original Barker studies, a longitudinal study in Finland demonstrated that women born
of LBW and experienced rapid postnatal growth were associated with the development of
coronary heart disease in later life99. In another study, this “catch-up growth” in LBW

16

children was also strongly associated with an impaired glucose tolerance at seven years of
age100. Alarmingly, this accelerated period of growth resulting from sub-optimal in utero
environments, is highly correlated with CVD development. A Finnish study reported that
the highest death rates from coronary heart disease were from children who were thin at
birth, but had caught up to average body weight by childhood101. These studies provide
strong evidence for the role of “catch-up growth” in exacerbating growth restricted
individuals and programming of diseases in later life. Interestingly, the current arbitrary
birth weight cut-off in IUGR categorization cannot account for the possibility that
newborns above the 10th percentile can also be exposed to an adverse in utero
environment63. The inappropriate growth patterns associated with insufficient in utero
environments can still be present despite not being reflected in birth weight outcomes. In
support, a study reported that accelerated growth during the first 4 months of post-natal life
is associated with childhood obesity, and is also independent of birth weight64. Therefore
inferring that the accelerated growth pattern maybe a more crucial factor behind the adverse
health outcomes than birth weight alone. In support, risk of chronic disease development
have also been demonstrated to occur independent of birth weight102,103. This highlights the
possibility that the risk of disease development is not solely caused by a drop in
birthweight, but by a combination of in utero induced stress factors, and an accelerated
growth pattern. As a result, it is important to further examine the underlying processes
behind fetal programming of CVD development in later life and the contributions of a
postnatal catch up growth.
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1.2.4

Fetal Programming of CVDs

Barker and colleagues initially demonstrated that mortality from heart diseases are
strongly associated with fetal programming, both animal and human studies continued to
support Barker’s original work and add further understanding to the in utero programmed
mechanisms underlying development of diseases in later life104–106.
Mechanisms such as in utero hypoxia have been known to alter heart development,
and suppress cardiac contractility107,108. Specifically, in utero insults are also associated
with the development of cardiac hypertrophy, and cardiac remodeling. For example, the
expression of pro-fibrotic genes, with discrete structural abnormalities such as deposition
of collagen in the heart at adolescence have been found in rats born of hypoxic IUGR 109.
Additionally, rats born from a hypoxic pregnancy also displayed left ventricular
enlargement at 12 months of age with strong indication of left ventricular dysfunction and
pulmonary hypertension110. Collectively, these studies suggests that IUGR individuals may
be predisposed to the development of CVDs in later life through these progressive cardiac
remodeling situations.
The programming of CVD such as cardiomyopathy may stem from placental
insufficiencies given that the placenta regulates flow of oxygen and necessary nutrients for
the fetus’ development. Amounting evidence have linked later life cardiovascular problems
early markers such as disturbed endothelial function, and persistent alterations in cardiac
metabolisms111,112. These manifestations can be traced back to the in utero environment.
For example, impedance to placental blood flow, a characteristic of PI, often results in the
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increase in placental bed resistance113,114. In order to overcome the mechanical force
required to eject against a high resistance vascular bed, abnormal fetal heart growth
typically occurs as adaptation. During post-natal life, this is associated with an increased
ventricular load, which can contribute to the development of cardiac hypertrophy113,114.
Interestingly, heart weights are not always altered in the placental restricted offspring,
however there is certainly a higher proportion of mononucleated cardiomyocytes as
demonstrated in a sheep model115. Furthermore, cardiomyocyte size relative to heart size
is increased in the placental insufficient offspring. Normally, cardiomyocytes undergo
binucleation during late gestation. However due to environmental factors such as placental
restriction, this process – an indicator of heart maturation – is delayed116,117. As a result,
chronic placental restriction results in delayed binucleation during development, and larger
but fewer cardiomyocytes at term115. These adaptions to chronic placental restriction are
risk factors for the development of cardiac hypertrophy in adulthood, and can have long
term consequences in later life. These studies altogether indicate the importance of fetal
programming as a predictor of cardiovascular complications in later life. In summary, it is
clear that in utero environments play a crucial role in later life disease development through
inappropriate growth adaptations. Furthermore, these adaptations, when challenged by
additional insults such as an unhealthy dietary pattern, can further increase the
susceptibility to CVD development in the offspring.
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1.3 Adverse Postnatal Diets

As previously mentioned in the fetal programming discussion, another critical
period in determining development of chronic diseases is the postnatal period. Specifically,
a mismatch between prenatal and postnatal environment can lead to the development of
metabolic complications in later life, as demonstrated by the Dutch hunger winter93. An
increasing concern in our modern society is believed to affect this said critical postnatal
growth period. This concern is known as the “Western Diet” (WD), which is characterized
by high saturated fats, and high sugar contents118,119. According to the World Health
Organization, the consumption of this energy-dense diet combined with the lack of physical
activity are the fundamental causes of obesity. Recent estimates of world-wide obesity rates
is at 10%, with more than 40 million children categorized as overweight or obese120. As
American corporations expand their fast food empire into developing countries, rates of
obesity has also risen approximately 30%120. It therefore draws to our attention, how the
mismatch between restricted in utero environments and an energy dense postnatal diet may
affect health in adulthood

1.3.1

Cardiovascular Dysfunction and WD

The most concerning aspect of the consumption of a WD and increased Body Mass
Index (BMI) is the risk of developing CVDs in adulthood120. In an eight year study, men
aged 40-75 years whom, according to a questionnaire, declared a frequent consumption of
WD had a higher risk of developing cardiovascular diseases compared to men who
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primarily consumed a prudent diet121. A more recent study using logistic regression
demonstrated that, after adjusting for coronary risk factors, women whom consumes
processed meats, and sugars have a higher relative risk for heart diseases119. These
epidemiological studies demonstrates that unhealthy dietary patterns such as the WD
closely predicts the risk of CVDs later in life. Several animal studies also attempted to
investigate the underlying mechanisms of this association. For example, a recent study
demonstrated that rats fed with a high fat diet were associated with mild reduction in
ejection fraction, increased left ventricular mass and IR122. As previously discussed, a state
of IR in the heart is strongly associated with cardiac remodeling and heart failure123.
However, this insulin resistant state can be attributed to the consumption of diet high in
fats such as the WD. In response, to the high levels of fatty acids, cardiomyocytes increase
its expression of CD36 transporter for fatty acid uptake, and reduce GLUT4 mediated
glucose uptake124,125. Maladaptation in the saturated fatty acid oxidation often leads to the
increase in its by-product: reactive oxygen species (ROS), and the accumulation of lipid
intermediates such as diacylglycerol (DAG), and ceramide126. In turn, ROS and DAG are
associated with the inhibition of serine phosphorylation of IRS-1 in the insulin signaling
pathway. In addition, ceramide is also associated with the inhibition of AKT127. As a result,
increased saturated fatty acids, and lipid intermediates can impair the heart’s ability to
uptake glucose, resulting in IR. Furthermore, ROS is also associated with cardiac
hypertrophy, where it has been shown to activate mitogen-activated protein kinases, and
matrix metalloproteinase (MMP) involved in extracellular matrix remodeling and
fibrosis128,129.
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Despite its importance to cardiac metabolism, the consequences of the change
towards fatty acid oxidation is not completely understood. Take for example a study in
2006 which examined the effects of high fat diets on the development of left ventricular
remodeling in response to hypertension. Compared to a low fat diet, rats fed on a high fat
diet (60% of total energy) did not demonstrate increases in left ventricular mass, myocyte
cross-sectional area130. This suggests that a switch towards increased fatty acid oxidation
can improve heart failure outcomes of hypertensive, and high fat diet fed rats. However,
other studies have suggested that this may be due to the differential effects of saturated and
unsaturated fatty acid content. Specifically, rats fed on saturated fatty acids demonstrated
increased cardiomyocyte apoptosis compared to rats fed on unsaturated fatty acids,
possibly due to an association with increased ceramide content131. In addition, another
study demonstrated that rats developed contractile dysfunction when fed a WD (which
contains a higher carbohydrate content), but not when fed a strictly high-fat diet118. This
difference may be attributed to the fatty acid oxidation maladaptation, and the induction of
fatty acid responsive genes associated with WD feeding. Considering the evidences
presented, fatty acid oxidation surely plays an important and dynamic role in the
development of heart failure. It is also evident that prolonged WD feeding is indeed
associated with development of heart failure and cardiac remodeling due to maladapted
fatty acid oxidation. With a significant portion of our population already predisposed to
later life CVD development from in utero origins, the consumption of such unhealthy
dietary patterns may exacerbate the existing consequences. Particularly, it can result in an
earlier expression of the disease phenotype, and thus warrants our attention to new reliable
diagnosis techniques in order to provide earlier intervention.
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Abnormal Placental Function
(Placental Insufficiency,
Hypoxia)
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Figure 1.1 Prenatal and Postnatal Factors That May Contribute to the Development
of Cardiovascular Diseases in Adult Life. In utero insults such as PI, or poor maternal
diet induces an unfavorable intrauterine environment, resulting in intrauterine growth
restriction, and a low birth weight outcome. This predisposes the offspring to a period of
rapid catch-up growth, associated with development of many adult diseases. This can be
further aggravated by a postnatal insult from WD consumption. By adulthood, this may
lead to the emergence of markers of CVDs such as IR, and disruptions in coronary blood
flow. Eventually, these factors contribute to the development of a severe CVD.
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1.4 Methods for Studying Cardiac Blood Flow and Metabolism

1.4.1

Doppler Ultrasound

Although currently there are no clinical technique available which allows the direct
visualization of the coronary microcirculation, techniques which measures coronary blood
flow are commonly used to assess the function of microvasculature. Several of these
techniques utilizes the Doppler principle which allows the measurement of instantaneous
changes in coronary blood flow. One such example is the Doppler catheter technique.
Introduced in the 1970s by Hartley and Cole, it utilizes a piezoelectric crystal tipped
catheter placed at the coronary ostium132,133. In addition, the introduction of the Dopplertipped guide wires, the 90s also saw the use of intracoronary flow measurement as an
accepted approach in coronary blood flow measurements134. This method utilizes a thin
flexible steerable guide wire with an ultrasound transducer tip which is placed in the left
circumflex coronary artery. It offers improvement over the thicker Doppler catheters which
are prone to alteration of velocity profile and obstruction of vessel135. Both of the Doppler
techniques have already been established as useful techniques, however they require
invasive catheterization, which may limit its usefulness as a clinical assessment of CVD
development. In addition, although the use of Doppler catheters or wire are determined to
be safe, severe complications such as bradycardia and coronary spasms can occur134. As a
result, a safer, and equally reliable non-invasive technique in coronary flow, and perfusion
measurements should be explored.
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1.4.2

Echocardiography

Echocardiography is performed by placing an ultrasound transducer on the chest
wall of the subject, which creates two-dimensional images of the heart136. It can provide
detailed information such as ventricular wall thickness, and the size and shape of the heart.
In addition, it is also capable of calculating ejection fraction, cardiac output and diastolic
function by estimating the changes of ventricle size during diastole and systole137. As a
result, the use of echocardiography is common amongst physicians for the diagnosis of
cardiomyopathies and hypertrophy. Additionally advancements in ultrasound technology
also allows the measurement of coronary flow using the Transthoracic Doppler
Echocardiography (TTDE) technique. Specifically, the TTDE utilizes pulsed wave
Doppler echocardiography and color Doppler flow mapping for the measurement of flow
at

the left

anterior

descending coronary artery136,138.

The advantageous

of

echocardiography is that it provides a non-invasive assessment of various heart functions
with no known risks or side effects. However results from echocardiography may be very
operator dependent, and thus lack specificity139. More importantly, the measurement of
heart functions such as cardiac output are end point measurements, and not early diagnostic
targets prior to the onset of diseases.

1.4.3

Positron Emission Tomography
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Positron Emission Tomography (PET) is a highly sensitive modality which
provides localization of radioactively labeled tracer concentrations through the detection
of gamma rays resulting from positron annihilation140. These tracers can provide important
hemodynamic and metabolic information. In patients with hypertrophic cardiomyopathy,
coronary blood flow reserve measured with 15O-labelled water and 13N-labelled ammonia
has been shown to be decreased49,141. Similarly, patients with dilated cardiomyopathy also
demonstrated an abnormal coronary reserve measured by 15O-labelled water142.
Measurement of perfusion parameters are also typically performed in conjunction
with cardiac metabolism imaging. Measurement of cardiac metabolic rate is typically
achieved by
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F-2-fluoro-2-deoxy-d-glucose (18F -FDG) tracer. [18F] FDG is a glucose

analog which is taken up by tissues such as the heart, muscle, and liver. However, [18F]
FDG cannot be metabolized due to the hydroxyl group at 2’ position substituted with a
radioactive isotope
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F, As a result, the measured activity of [18F] FDG is indicative of

glucose uptake, and degree of glycolysis143. The use of [18F] FDG as indicators of tissue
insulin sensitivity is common in clinical practice. For example a study with [18F] FDG PET
clearly demonstrated that insulin sensitivity was highly associated with increased glucose
uptake in the liver144,145. Furthermore, [18F] FDG PET can also be used to determine
myocardial viability, using the criteria of low perfusion and low metabolism145,146. In
summary, PET offers a well-established, and non-invasive method for the measurement of
hemodynamic and metabolic parameters in the target organ. However, PET requires the
injection of radioactive tracers, and exposure to ionizing radiation. Nonetheless, PET is an
important imaging modality in research due to its ability to detect problems prior to actual
onset of diseases.
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1.4.4

Dynamic Contrast Enhanced Computed Tomography

Developed in the 1970s, Dynamic Contrast Enhanced Computed Tomography
(DCE-CT) aims to provide a non-invasive solution to the study of hemodynamics in
tissue147. However due to limitations in spatial and temporal resolution during its infancy,
the widespread use of DCE-CT failed to gain traction. Fortunately, over the next couple of
decades, significant advancements in CT technology have addressed these limitations and
propelled DCE-CT to be a competitive imaging modality with wide clinical acceptance.
For example, development of slip-ring technology has dramatically improved temporal
resolutions. In addition, advancements in detector technology has allowed the imaging of
whole organs in a single study. As a result, DCE-CT has become an excellent diagnostic
tool in the study of vascular changes, and coronary circulation associated with CVDs148–
150

. In comparison to the previously mentioned modalities, DCE-CT provides a more

complete evaluation of tissue hemodynamics with its capability to measure perfusion,
blood volume, mean transit time, and capillary permeability surface area product in a single
study151. In comparison to MRI, DCE-CT may appear disadvantaged due to the use of
ionizing radiation. However, the gadolinium-based contrast agent used in contrastenhanced MR lacks a linear relationship between signal intensity and concentration. In
contrast, DCE-CT provides a linear relationship between iodine contrast concentration and
X-ray attenuation152.
Several studies in cardiac imaging have given solid validation to the use of DCECT as a reliable diagnostic tool. One such study, recruited patients with coronary artery
disease with varying degree of stenosis as classified from catheter-based angiograms.
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DCE-CT with dipyridamole infusion as performed, and analyzed to calculate myocardial
blood flow, and blood volume. The results demonstrated that blood flow is significantly
lower in stenosed patients, and that DCE-CT appeared to be a useful predictor of
functionally significant coronary stenosis150. In another evaluation of the use of CT
perfusion, it demonstrated a high sensitivity and specificity in diagnosis of chest pain from
coronary stenosis149.
In DCE-CT imaging, X-ray iodinated contrast agent is injected in peripheral vein,
while the CT scanner image the passage of contrast through the myocardium. Two
assumptions must be made in perfusion calculations: first is the uniform distribution of
iodinated contrast through the vascular system. Second, is that the increase in attenuation
in tissue is proportional to the concentration of contrast agent153. Typically, CT scanner
scans the region of interest continuously for a prolonged acquisition period which captures
the slow leakage of contrast from blood vessels into interstitial space. The algorithm used
in DCE-CT is based on the approximation of the Johnson-Wilson model which explains
the bidirectional exchange of contrast between the capillaries and the interstitium. This
adiabatic approximation assumes that changes in tracer concentration are slower in
parenchymal tissue compared to that in capillaries154. With the algorithm it is then possible
to calculate blood flow and display the values in rainbow colored functional maps.
DCE-CT is an excellent imaging modality for the study of hemodynamical changes.
It is non-invasive and widely available in hospitals, with rapid scan times. More
importantly, it can image soft tissues, bone, and blood vessels with excellent temporal and
spatial resolution. However, a major drawback of DCE-CT is the exposure to carcinogenic
ionizing radiation. In addition, the injection of contrast agents which may impair renal
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functions. Nonetheless, the use of DCE-CT may potentially provide a means to monitor
for the onset and progression of diseases such as CVDs.
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1.5 Research Goals

The objective of this thesis was to investigate the combined effects of in utero
insults from placental insufficiency, or high energy diets during pregnancy, combined with
an adverse postnatal diets on the development of CVDs in early adulthood. In addition, this
project aimed to assess the use of DCE-CT and PET in the study of CVDs in a guinea pig
model. In this regard, the two primary goals of the thesis were as follows:
1) Investigate the effects of placental insufficiency induced low birth weight and
postnatal Western diet on the development of CVD in a guinea pig model with
DCE-CT and PET imaging.
2) Examine the effects of high energy maternal diet and postnatal Western diet on
the development of CVD in a guinea model with DCE-CT and PET imaging.
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2

The Impact of an Adverse In Utero Environment Resulting in Low Birth
Weight, and a Postnatal Wester Diet on Early Development of Cardiovascular
Diseases in Guinea Pigs
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2.1

Introduction

Cardiovascular Diseases (CVDs) are the leading causes of mortality world-wide,
accounting for more than 17 million deaths in 2008 alone1. Characterized by cardiac
remodeling and metabolic dysfunction processes, notable types of CVDs such as
cardiomyopathy are typically associated with cardiac failure2–6. Traditionally, risk factors
for CVD development are mostly attributed to life-style choices such as tobacco use,
physical inactivity, or unhealthy dietary patterns7,8. Indeed, diets such as the increasingly
prevalent Western Diet (WD), with its high levels of processed carbohydrates and saturated
fatty acids, is strongly associated with an increasing risk of CVD development9,10.
Interestingly, amounting evidence now also highlights the importance of intrauterine
environment as a risk factor for developing chronic diseases in later life, particularly in
cases of intrauterine growth restriction (IUGR)11.
IUGR is defined as the inability of the fetus to reach its expected growth potential,
often resulting in low birth weight (LBW)12. A common cause of IUGR is placental
insufficiency (PI), where the placenta fails to provide optimal oxygen and nutrient supply
to the fetus13,14. Clinically, IUGR is categorized as birthweight falling below the 10th
percentile12. However, this categorization method based on an arbitrary birthweight underrepresents newborns which lie outside the cut-off but are still exposed to the same suboptimal in utero environment15. For example, the development of severe adult diseases
from in utero insults have been shown to occur independent of birthweight changes16. It is
more likely that programming for disease development stems from a combination of in
utero induced stress factors and an irregular developmental profile such as accelerated
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catch-up growth in early postnatal life17,18. Of additional concern are evidence which
highlight that in utero programmed changes can further sensitize and accelerate the
development of CVDs from postnatal insults19. Amidst the increasing prevalence of WD,
infants born from adverse in utero environments may become more susceptible to the
enhanced deleterious effects of a growth restricted development profile. However our
understanding of the relationship between prenatal and postnatal insults on offspring
disease development has yet to be thoroughly investigated.
Part of this investigation is to understand the developmental progressions of CVDs
prior to the onset of more severe consequences. Disease progression in the myocardium is
often in concert with impairments in coronary blood flow, and metabolic alterations such
as increased fatty acid oxidation, and cardiac insulin resistance (IR)6,20–23. Collectively,
these are pre-clinical hallmarks of early CVD progression, and can be valuable markers for
diagnosis. With the advancements in non-invasive imaging modalities commonly used in
cancer diagnoses, these applications are now beginning to expand to the field of
cardiovascular diagnoses. For example, new developments in Dynamic Contrast Enhanced
Computed Tomography (DCE-CT) allows accessible, and non-invasive assessment of
coronary flow and perfusion in the coronary microvasculature24,25. Additionally, Positron
Emission Tomography (PET) has been extensively used to measure tissue specific glucose
uptake, an indicator of IR26. These imaging modalities can prove to be valuable resources
in identifying at risk individuals, monitoring disease progression, and potentially setting
the stage for the development of more preventative therapies.
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Understanding the relationship between the prevalence of CVDs and its risk factors
is crucial in efforts to minimize harmful societal impact. The purpose of this study was to
utilize DCE-CT and PET imaging supported by traditional molecular techniques to
examine the developmental profile associated with early CVD development in a guinea pig
model of in utero growth restriction and postnatal dietary insult. We postulated that
offspring born of LBW– a marker of inadequate in utero growth – would exhibit preclinical markers of cardiac dysfunction, including disruptions in basal coronary flow, and
cardiac glucose metabolism by early adulthood. Additionally, we postulated that the
combination of LBW and a postnatal WD would result in an accelerated advancement of
these CVD development parameters
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2.2 Methods

2.2.1

Animals

Pregnant Dunkin-Hartly guinea pigs (Charles River Laboratories, Wilmington,
MA) were fed ad libitum guinea pig chow (LabDiet diet 5025: 27% protein, 13% fat, 60%
carbohydrates), and housed in individual cages (20 ± 2°C, and 30-40% humidity) with a
12 hour/light dark cycle. Uterine artery ablation (UAA) procedure was selected to impair
placental function, fetal growth, and induce markers of CVD27,28. Briefly, all pregnant
guinea pigs at mid gestation (~32 days) were placed in an anesthetic chamber (4-5%
isoflurane with 2 L/min O2, and maintained at 2-3% isoflurane with 1 L/min O2) and
immediately after induction, a subcutaneous injection of Robinul (0.01 mg/kg
glycopyrrolate; Sandoz Canada, Montreal, QC) was administered. A midline incision was
made below the umbilicus to expose the mesometrium of one horn of the uterus, where
every second arterial vessel branch was cauterized using an Aaron 2250 electrosurgical
generator (Bovie Medical, Clearwater, FL). Following surgery, a subcutaneous injection
of Temgesic (0.025 mg/kg buprenophrine; Scherin-Plough, Kenilworth, NJ) was
administered. Sows delivered naturally, and within 12 hours, birth weights and crown rump
of each pup were recorded. At the end of the pupping period, guinea pig pups were defined
as normal birth weight (NBW) if their birth weights were between 25th to 75th percentiles,
and LBW if below the 25th percentile. Based on this criteria, and in accordance with
previous UAA and maternal feed restriction guinea pig models,

NBW pups were

determined to be greater than 90g, while LBW pups were determined to be below 85g29–
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31

. All pups were weighed daily from birth until 15 days of age, where pups were weaned

and randomly assigned onto either a control diet (CD) (TD: 110240, Harlan Laboratories,
Madison WI), or a WD (TD: 110239, Harlan Laboratories, Madison WI). Both CD and
WD contained 21% protein (% of total kcal). However, these diets differed in
carbohydrates and fat, wherein CD contained 60% carbohydrates [distribution (% by
weight): 35% corn starch, 10% sucrose], and 18.4% fats, while WD contained 33%
carbohydrates [distribution (% by weight): 19% sucrose, 6.5% fructose] and 45% fats. In
addition, composition of fats also differed, wherein CD consisted of 2.8% saturated fatty
acids (SFA), 4.4% monounsaturated fatty acids (MUFA), and 11.2% polyunsaturated fatty
acids (PUFA), while WD consisted of 31.7% SFA, 11.8% MUFA, 1.8% PUFA
[distribution (% of total kcal)] (Table 2.1). In total, CD contained 3.4 kcal/g while WD
contained 4.2 kcal/g energy. Guinea pigs were housed in individual cages at 20°C and 3040% humidity with 12 hour light-dark cycle. Food intake was recorded daily and body
weights were recorded twice weekly until putdown at young adulthood (150 days). The
resulting division in groups for the study was NBW/CD, NBW/WD, LBW/CD, and
LBW/WD, which was further divided by sex.
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Table 2.1 Diet Composition

Diet Component

Control Diet (CD) Western Diet (WD)

Total Protein (%kcal)

22

21

Total Fat (%kcal)

18

46

Saturated Fatty Acids

15

70

Polyunsaturated Fatty Acids

61

4

Monounsaturated Fatty Acids

24

26

Total Carbohydrate (%kcal)

60

33

Sucrose

11

22
-

Fructose

7.6

Cholesterol (%kcal)

-

0.25

Density (kcal/g)

3.4

4.2
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2.2.2

Imaging

Guinea pigs underwent DCE-CT and PET imaging at 50 and 110 days of life. The
scan time point of 110 days or early adulthood was selected based on a previous study,
which investigated IUGR/LBW associated changes in whole body glucose tolerance and
reported alterations in offspring glucose tolerance at 101 days32. The earlier time point of
50 days was selected to investigate possible developmental changes prior to young
adulthood an active post weaning growth phase, as previous studies using the UAA model
have demonstrated increased cardiac and renal fibrosis at 60 days of age28. Prior to
scanning, baseline glucose levels were measured using a Bayer Contour glucometer (Bayer
Diabetes, Mississauga, ON). In addition, during scanning, heart rate, respiration rate and
arterial O2 saturation were monitored and recorded using MouseOx pulse oximeter for
small animals (Starr Life Science Corp, Oakmont PA).

2.2.3

Dynamic Contrast Enhanced Computed Tomography

DCE-CT scans were performed using a clinical GE multi-slice CT scanner
(Discovery VCT, GE Healthcare, Waukesha, Wis). Guinea pigs were anaesthetized in an
anesthetic chamber (4-5% isoflurane with 2 L/min O2), before transferred to a tight fitting
nose cone to maintain anesthesia with 2-3% isoflurane at a flow rate of 1 L/min. Once
anesthesia was stably established (absence of response to pain stimuli), guinea pigs were
positioned in the center of the CT scanner. A scout localization scan was performed to find
the slice locations of the heart. A two phase dynamic scan of the heart at the determined
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slice locations was conducted following an injection of 1mL/kg of iodinated contrast
(Omnipaque 200mgI/mL) via a pedal vein catheter at 8 mL/min. In the first phase of the
dynamic scan, images were acquired continuously at every second for 14.6 seconds at a
tube rotation speed of one revolution per second, voltage of 120 kV and current of 180 mA.
This was followed by the second phase where images were acquired every 15 seconds for
200 seconds using the same scan parameters (tube voltage, current, and rotation speed) as
the first phase. The dynamic images were reconstructed with the GE Healthcare proprietary
detail filter with a slice thickness of 1.25mm. The reconstructed images were transferred
to an image processing workstation (Advantage Windows 4; GE Healthcare, Waukesha
Wis). Using CT Perfusion 5 program (GE Healthcare, Waukesha, Wis), an arterial input
curve of contrast medium concentration was generated with a region of interest (ROI)
placed in the left ventricle chamber of a slice which showed the maximum size of the
chamber. Following which, another ROI was outlined around the contour of the heart in
the first image of the dynamic series of the same slice. Subsequent images which did not
conform to this heart outline were removed from the study as they were mis-registered with
the first image from either breathing or cardiac motion of the animal. Blood flow maps of
the chosen slice were generated with the CT Perfusion 5 software (GE Healthcare,
Waukesha, Wis.). Myocardial blood flow was calculated as the mean pixel value in a ROI
placed in the inferior wall of the left ventricle where it is least affected by either respiratory
or cardiac motion.

2.2.4

Position Emission Tomography
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Guinea pigs were first anaesthetized in an air-tight box with 4-5% isoflurane at 2L/min,
and injected with ~25kBq/kg (0.2-0.3mL) of [18F]- fluoro-deoxy-glucose ([18F] FDG) via
the pedal vein. Animals were then recovered, returned to their cage, and placed in a lead
brick shield. Approximately 40 minutes later, they were again anaesthetized with 4-5%
isoflurane as before, and placed on the bed of a micro-PET scanner (GE eXplore Vista DR,
GE Healthcare, Waukesha, Wis). Anesthesia was maintained with a nose cone through
which 2.5-3% isoflurane was flowing at the rate of 1L/min, and a 20 minute emission scan
of the heart region was then acquired.
After correction for scatter and random coincidences, the scan was reconstructed
into sixty 0.78mm thick slices. The reconstructed images were analyzed using an in-house
MATLAB program (MathWorks Inc., MA, USA). For each slice in which the left ventricle
was visible for analysis, two ROIs were drawn: one outlining the epicardial surface, and
the other one the endocardial surface of the left ventricle. The difference in the total counts
was divided by the difference in volume of the ROIs to arrive at the average count in the
myocardium. This average was converted to activity (Bq) using a sensitivity calibration
factor determined from routine quality assurance of the scanner. The image derived
activities from all LV slices were averaged together to calculate myocardial activity.
Standardized Uptake Value (SUV) in the left ventricular myocardium was calculated as:

𝑆𝑈𝑉 =

𝑀𝑦𝑜𝑐𝑎𝑟𝑑𝑖𝑎𝑙 𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦
𝐼𝑛𝑗𝑒𝑐𝑡𝑒𝑑 𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦 ⁄𝐵𝑜𝑑𝑦 𝑊𝑒𝑖𝑔ℎ𝑡

(1)

56

2.2.5

Tissue Collection

Following a recovery period after the 110 day scan, at postnatal day 143±1.9,
animals were sacrificed by CO2 inhalation following an overnight fast33. The heart was
removed, trimmed of connective tissue, weighed, and carefully separated into left or right
ventricles. A coronal cross section above the apex of the left ventricle of approximately
3mm thick was placed in 4% paraformaldehyde for histological analyses34. The remainder
of the left ventricle was frozen in liquid nitrogen for RNA and protein analysis.

2.2.6

Quantitative Real-Time PCR

Flash frozen left ventricular tissues were homogenized in Trizol® (Invitrogen Life
Technologies Co., Burlington, ON), followed by 200 µL of chloroform for each tissue
sample. The mixed solution was centrifuged at 12,000g for 15 minutes at 4°C. The resulting
aqueous phase was transferred to new RNAse-free tubes, and 500 µL of isopropyl alcohol
was added. The new solution was centrifuged at 12,000g for 10 minutes at 4°C to obtain
RNA precipitate. Following three 75% ethanol washes at 7500g for 5 minutes, the RNA
pellet was reconstituted in RNAase free diethylpyrocarbonate water. Yield and quality
(A260/A280 ration) of RNA was determined with NanoDrop 2000 UV-Vis
Spectrophotometer (Thermo Scientific, Waltham MA, US). Isolated RNA (4µg) were
reverse transcribed into complementary DNA with M-MLV Reverse Transcriptase
(Invitrogen Life Technologies Co., Burlington ON). Real-time qPCR was performed for
each sample in duplicate and was completed using a Bio-Rad CFX384 real time PCR

57

detector (Bio-Rad Laboratories Mississauga, ON) at a denaturing temperature of 95°C,
annealing temperature of 59.5°C, and elongation temperature of 72°C for 39 cycles. Data
are presented as a fold change in expression compared to NBW/CD exposed animals. The
2-ΔCT method with β-Actin as housekeeping gene was used for analysis35. Primer sets are
listed in Appendix A.

2.2.7

Western Blot

Flash frozen left ventricular tissues were pulverized and homogenized in RIPA lysis
buffer (50 mM Tris-HCl, NP-40 1%, Na-deoxycholate 0.25%, 1mM EDTA, 150 mM
NaCl, 50 mM NAF, 1mM NaV, 25 mM β-glycerophosphate, pH 7.4) with protease and
phosphatase inhibitor. Homogenates were centrifuged at 10,000g for 15 minutes at 4°C.
Supernatants were transferred to fresh tubes and used as protein preparations, which were
quantified with DC™ Protein Assay Kit (Bio-Rad Laboratories, Mississauga, ON).
Loading samples of 30 µg protein were then separated by size on 6% Bis-Tris gels, and
transferred on to nitrocellulose membranes for an overnight block with 5% bovine serum
albumin at 4°C. Blots were then probed with AKT-1 (Cell Signaling® #4691, 1:1000),
pAKT Serine 473 (Cell Signaling® #9271, 1:1000), pAKT Threonine 308 (Cell
Signaling® #9275, 1:1000), and monoclonal horseradish peroxidase-conjugated β-actin
Sigma-Aldrich #A3854, 1:50000) diluted in 5% bovine serum albumin in Tris-buffered
saline/Tween 20 (0.01%) for 1 hour at room temperature. Blots were then probed with
horseradish peroxidase conjugated goat anti-rabbit IgG (Cell Signaling® #7074, 1:1000)
secondary antibody diluted in 5% bovine serum albumin in Tris-buffered saline/Tween 20
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(0.01%) for 1 hour at room temperature. Immunoreactive bands were detected using
Luminata Forte Western HRP Substrate chemi-luminescence (EMD Millipore, Darmstadt,
Germany), and imaged with VersaDoc Imaging System (Bio-Rad Laboratories
Mississauga, ON). Densitometry values (arbitrary units) were determined using the
ImageLab software (Bio-Rad Laboratories, Mississauga, ON), and the abundance of
proteins were expressed relative to β-Actin.

2.2.8

Histological Analysis

Immediately following putdown, coronal cross-sections of the guinea pig left
ventricles were collected in 4% paraformaldehyde, embedded in paraffin, and then sliced
in 5µm sections. Paraffin-embedded sections were stained with hematoxylin and eosin
(H&E) or Masson’s trichrome for histological analysis of hypertrophy, inflammation and
fibrosis. Eight non-overlapping colored images of the H&E stained slides were obtained at
200x magnification using Leica DMI 6000B microscope (Leica Microsystems, Wetzlar,
Germany). Utilizing Leica MMAF software (v1.40, Leica Microsystems, Wetzlar,
Germany), cardiomyocytes with visible nuclei was outlined in each of the eight nonoverlapping images. The cardiomyocyte cross sectional area were calculated in square
micrometers, and averaged between the non-overlapping images as per previous studies on
cardiac hypertrophy36. Similarly, eight non-overlapping colored images of the Masson’s
trichrome stained sections were obtained at 100x magnification. Again, utilizing the Leica
MMAF program, areas of the blue stained collagen fields were measured and divided by
the total area of the field, omitting the voids36,37. The collagen fractions of each section
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were then expressed as the mean percentage of collagen. Analysis of the histological
sections were performed under blinded conditions.

2.2.9

Statistical Analysis

Statistical Analysis was performed with SPSS software (SPSS v22.0, Chicago, IL,
USA). A mixed model ANOVA analysis was used to determine significant differences
(p<0.05) from sex, age, birth weight, and postnatal diet. If significant differences or
interactions were determined, student t-tests were used for post-hoc analyses of differences
between groups.
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2.3 Results

2.3.1

Birthweight and Development

Clinically, determination of growth restriction is arbitrary assigned based on
measurement of birth weight (<10th percentile)38. Similarly, this study categorized LBW, a
proxy for growth restriction, as offspring whose birthweight fell below the 25th percentile
of mean birth weights. As a result, pups which were categorized as LBW were 29% lighter
at birth compared to those which were categorized as NBW, independent of sex (Figure
2.1, p<0.05). In addition, at birth these LBW offspring displayed a lower Weight/Length
ratio, a measure of leanness (Figure 2.1, p<0.05), which have been previously observed in
other models of IUGR32. By putdown at 143±1.9 days, these LBW offspring displayed
similar body weights to that of the NBW group, however, females demonstrated a diet
induced reduction in bodyweight (Figure 2.2, p<0.05). Moreover, heart weight relative to
body weight was not significantly altered between groups (Figure 2.2).
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Figure 2.1 Characteristics at Birth. Pups were categorized as LBW group based on a
pre-established cut-off determined as below the 25th percentile of average birth weights.
Birth weight of A) female, B) male guinea pig pups were recorded. N=18 (NBW), N=11
(LBW) in females, and N=13 (NBW), N=13 (LBW) in males. In addition, ratio of birth
weight over crown rump length of C) female, and D) male guinea pig pups was determined.
N=13 (NBW), N=8 (LBW) in females, and N=12 (NBW), N=10 (LBW) in males.
*p<0.05. Box represents Mean and SEM, while whiskers represents Max and Min values.
Statistical significance was determined by student’s t-test.
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Figure 2.2 Putdown Characteristics. Bodyweights of A) female and B) male guinea pigs.
Percent ratio of heart weight relative to body weight at of C) female and D) males at day
143 ± 1.9. N=8 (NBW/CD), 10 (NBW/WD), 5 (LBW/CD), 6 (LBW/WD) for females. N=6
(NBW/CD), 7 (NBW/WD), 6 (LBW/CD), 7 (LBW/WD) for males. *p<0.05. Box
represents Mean and SEM, while whiskers represents Max and Min values. Statistical
analysis performed by two-way ANOVA.
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2.3.2

LBW Resulted in Reduction in Basal Coronary Blood Flow in Young Adulthood

Following a 2 hour fast, and just prior to DCE-CT and PET scanning, animals from
all four treatment groups, displayed a similar glucose level of 9.1 ± 0.4 mmol/L. During
scanning, the animals maintained an average heart rate of 205±24 bmp, and an average
oxygen saturation above 98%. No significant deviations in these physical parameters were
observed during the 40 minute scan period (Table 2.2).
Coronary vascular dysfunction often occurs with the increasing severity of cardiac
hypertrophy, and cardiomyopathy20,39,40. More importantly, alterations in coronary flow
and microvasculature precedes heart failure, and is known to be a strong predictor of
hypertrophic cardiomyopathy41. Using DCE-CT, basal coronary flow in the inferior wall
of the left ventricle was determined at 50 and 110 days. A significant birthweight and age
interaction was observed, where coronary flow of LBW guinea pigs was reduced by 17%
compared to NBW as they reach adulthood (Figure 2.3, p<0.05). In comparison, NBW
animals demonstrated a 10% increase in coronary blood flow as they reach adulthood.
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Table 2.2 Baseline Physiological Parameters during Scanning Procedures. Average
baseline readings of glucose, heart rate, and oxygen saturation during CT and PET scanning
at (A) 50 days, and (B) 110 days. Data presented as mean ± standard error. N=12
(NBW/CD), 14 (NBW/WD), 7 (LBW/CD), 6 (LBW/WD) for females. N=9 (NBW/CD), 9
(NBW/WD), 5 (LBW/CD), 3 (LBW/WD) for males. Statistical significance examined by
two-way ANOVA.
Heart Rate
Sex
BW
Diet
Glucose
O2 Saturation (%)
(bpm)
Female

NBW

LBW

Male

NBW

LBW

CD

9.33±1.05

243.6±9.7

98.4±0.9

WD

9.85±0.91

232.9±7.9

97.7±0.7

CD

8.02±1.29

250.1±9.7

97.6±0.9

WD

8.45±1.82

234.7±13.7

97.6±1.2

CD

10.56±0.86

228.9±9.0

98.4±0.8

WD

8.80±0.97

261.0±9.7

96.9±0.9

CD

10.64±1.15

220.9±9.0

97.7±0.8

WD

8.40±1.29

235.5±10.6

96.8±0.9

Significance

ns

ns

ns

Sex

BW

Diet

Glucose

Heart Rate
(bpm)

O2 Saturation (%)

Female

NBW

CD

8.83±0.92

223.6±10.7

96.1±1.2

WD

8.35±0.58

217.9±6.8

98.0±0.7

CD

9.97±0.70

235.1±8.1

97.6±0.9

WD

8.73±0.92

207.4±10.7

97.8±1.2

CD

9.12±0.53

228.2±6.2

99.0±0.7

WD

8.25±0.75

224.3±8.8

99.2±1.0

CD

9.80±0.83

234.1±9.6

98.4±1.0

WD

8.65±0.92

223.6±9.6

97.6±1.0

Significance

ns

ns

ns

LBW

Male

NBW

LBW

65

B

A

260

* Interaction
NBW
LBW

mL/min/100g

240
220
200
180
160
140
50

ay
D

s

s
ay

0
11

D

Figure 2.3 Basal Coronary Blood Flow Determined by DCE-CT. A) Color coded blood
flow maps were calculated from DCE-CT, where cool colors represent areas of low blood
flow, while warm colors represent areas of high blood flow. B) Mean coronary blood flow
in the inferior wall of left ventricle at 50 and 110 days of post-natal life determined by CT
Perfusion software (GE Healthcare, Waukesha, Wis). *p<0.05 Interaction. N= 27 and 30
for 50 day old guinea pigs of NBW and LBW respectively, and N=18 and 22 for 110 day
old guinea pigs of NBW and LBW respectively. A repeated measures three-way ANOVA
was used to determine statistical significance. ANOVA table presented in Appendix C.
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2.3.3

WD Consumption Reduced Basal Glucose Uptake by Adulthood

In the development phase of many CVDs, the cardiac metabolic profile is often
altered, resulting in a state of IR42,43. Specifically, a switch in favor of fatty acid oxidation
was believed to be a protective mechanism against heart failure44. As a result, changes in
glucose metabolism, a proxy for determining IR, is a useful pre-clinical marker for diseases
such as hypertrophic cardiomyopathy.
Determination of basal cardiac glucose uptake at 50 and 110 days was completed
using [18F] FDG -PET. Where, chronic postnatal WD consumption resulted in a 21%
reduction in glucose uptake compared to CD groups at both time points (Figure 2.4,
p<0.05). No alterations in glucose uptake were influenced by birthweight.

67

A

B

5

SUV

4
3
2
1
0

D
W

D

C

*
Figure 2.4 Cardiac Glucose Uptake Determined by PET. A) Color coded image of F18 fluorodeoxyglucose ([18F] FDG) uptake determined by PET, where areas of warm colors
describe the intensity of [18F] FDG uptake. Standardized uptake value (SUV), a semiquantitative index of [18F] FDG uptake, and insulin sensitivity, was determined in the left
ventricle by defining a region of interest around the left ventricle. B) SUV of CD and WD
animals at both 50 and 110 day time points. N = 27 for CD fed animals and N=22 for WD
fed animals. *p<0.05. Box represents Mean and SEM, while whiskers represents Max and
Min values. A repeated measures three-way ANOVA was used to determine statistical
significance. ANOVA table presented in Appendix D.
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2.3.4

Cardiac Remodeling and Collagen Content Were Increased in LBW Offspring

Inadequate cardiac development, which is likely the result of adverse in utero
environments, combined with an accelerated growth profile may trigger the hypertrophic
growth of cardiomyocytes and proliferation of non-myocytes such as fibroblasts, therefore
setting the stage for pathological hypertrophy45,46. These cardiac remodeling processes are
crucial components in the eventual development of systolic dysfunction, and are strongly
associated with alterations in coronary circulation40. Following putdown, cross-sections of
left ventricles were analyzed for histological markers of hypertrophy and fibrosis. Heart
sections from LBW offspring displayed a 20% increase in cardiomyocyte cross-sectional
area compared to NBW offspring (Figure 2.5, p<0.05), indicative of a hypertrophic growth
phenotype.

2.3.5

Expressions of Collagen Increased in LBW Females

Enlargements in cardiomyocytes can be attributed to both classifications of cardiac
hypertrophy, which is physiological or pathological. However, pathological hypertrophy
differs in that it is characterized by fibrosis, particularly an excessive expression of
collagen47,48. In the LBW, and NBW/WD sections, a 1.9 fold increase in collagen
composition compared to NBW/CD sections was recorded, therefore highly suggestive of
a pathological hypertrophy phenotype (Figure 2.6, p<0.05).
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Additionally, the mRNA expression of pro-fibrotic genes as α smooth muscle actin
(α-SMA), Type 1 and 3 collagen, matrix metalloproteinase-1 (MMP1) and transforming
growth factor β (TGF-β) was determined (Table 2.3). These genes are known to play
important roles in the tissue fibrosis pathway49. A significant sex and birth weight
interaction for type 1 collagen mRNA was observed, where female LBW animals
demonstrated a significantly higher expression than NBW females (Figure 2.7, p<0.05).
The expression of the other targets, α-SMA, type 3 collagen, MMP1, and TGF-β were
consistent across sex, BW, and diet.

2.3.6

WD Feeding is Associated with a Reduction in AKT Activation

One of the main markers of CVD development is cardiac IR, an observation
reported in conjunction with WD consumption50,51. Specifically, the disruption of kinases
in the insulin stimulated glucose uptake pathway, such as insulin receptor substrate (IRS),
and Protein Kinase B (AKT), is an important marker behind tissue specific IR44,52,53. Other
reports in skeletal muscle also reported reductions in AKT activation, specifically
Threonine 308 (T308) and Serine 473 (S473), was strongly associated with growth
restriction54–56. In the current study, despite no alterations in pIRS protein expression,
pAKT (T308) to total AKT-1 was significantly reduced in female WD fed guinea pigs
(Figure 2.8, p<0.05), whereas males appeared to be unaffected by diet. Furthermore,
birthweight appeared to not confer any adverse impact in both sexes.
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Figure 2.5 Cross-Sectional Area of Cardiomyocytes.
A) Hematoxylin and Eosin stained
*
cross-sectional histological sections of left ventricles at putdown. Average cross-sectional
area (µm2) of cardiomyocytes in the left ventricle was determined between multiple
representative slides. White scale bar in representative images indicate 25 µm length. B)
Cardiomyocyte cross-sectional area between NBW and LBW animals. *p<0.05. N=15 for
NBW and N=13 for LBW animals. Box represents Mean and SEM, while whiskers
represents Max and Min values. Statistical significance was determined by a two-way
ANOVA. ANOVA table presented in Appendix E.
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Figure 2.6 Collagen Content in the Left Ventricle A) Trichrome stained histological
sections of left ventricle. Average area (µm2) of blue shaded collagen deposition was
determined as an indicator of fibrotic growth. White scale bar in representative images
indicate 100 µm length. B) % of Collagen deposition. *p<0.05 Interaction. N=8 for both CD
and WD fed NBW guinea pigs, and N=4 and 6 for CD and WD fed LBW guinea pigs,
respectively. Data presented as Mean ± SEM. Statistical differences determined by two-way
ANOVA. ANOVA table presented in Appendix F.
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Table 2.3 Relative mRNA Expression of Fibrotic Genes. Relative mRNA expression of
αSMA, Type 3 collagen, MMP-1, and TGFβ to Female NBW-CD group. No significant
differences were observed in the mRNA expression of these genes. N= 4 for NBW/CD,
NBW/WD, LBW/CD and LBW/WD in each sex. Statistical analysis completed by twoway ANOVA.

Sex

BW

Diet

αSMA

Female

NBW

CD
WD
CD
WD
CD
WD
CD
WD

1
1.07
1.12
0.78
0.71
0.36
0.43
0.79

LBW
Male

NBW
LBW

Type 3
Collagen
1
1.13
1.49
1.19
0.99
1.62
1.33
1.19

MMP-1

TGFβ

1
0.98
0.8
0.77
0.89
0.91
1.13
1.18

1
0.66
0.87
0.85
0.66
1.05
1.02
1.32

Relative Fold Expression
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Figure 2.7 Type 1 Collagen mRNA Expression. Relative mRNA expression of Type 1
Collagen in the left ventricle at 140 ± 1.9 day putdown. *p<0.05 Interaction. N= 4 for
NBW/CD, NBW/WD, LBW/CD and LBW/WD in each sex. Data presented as Mean ±
SEM. Statistical significance determined by two-way ANOVA. ANOVA table presented
in Appendix G.
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Figure 2.8 AKT Expression in the Left Ventricle at Putdown. Expression of pAKT
(T308) relative to total AKT-1 protein in the left ventricle at 140 ± 1.9 days of age. *p<0.05
Interaction. N= 4 for NBW/CD, NBW/WD, LBW/CD, and LBW/WD in both males and
females. Data presented as Mean ± SEM. Statistical significance determined by two-way
ANOVA. ANOVA table presented in Appendix H,
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2.4 Discussion

Adverse in utero environments such as PI are known risk factors for the
development of heart diseases in later life. Abnormal cardiac development processes which
result from growth restricted pregnancies are believed to underlie the development of
myocardial complications in later life34. Similarly, postnatal WD consumption is also
known to result in CVD development, including the onset of cardiac IR, and eventually,
cardiac dysfunction9,57. It can be inferred from these individual findings that the
predisposition of CVDs from in utero factors can further increase an individual’s
susceptibility to a secondary postnatal insult such as WD consumption. This study intended
to elucidate the independent and combined effects of LBW and WD on early markers of
impaired cardiac function in a guinea pig model. The principle findings of this study were
that 1) an adverse in utero environment resulting in LBW was associated with reduction in
resting coronary blood flow and the onset of pathological hypertrophy, and 2) postnatal
WD consumption resulted in reduced cardiac glucose uptake. Together, these findings in
early adulthood demonstrated that following an adverse in utero environment and a poor
postnatal diet, key pre-clinical markers of CVDs are present. Given that these early markers
are associated with severe cardiac dysfunction in later life, the current experiment
highlights an early stage of disease development that may serve as a platform from which
to undertake early intervention therapies.
The guinea pig was selected as an animal model in this study due to its similarities
to humans with respect to in utero developmental programming. Unlike other rodents,
guinea pigs are prenatal organ developers, where pups are mature at birth 58,59. For this
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reason, the guinea pig fetus is particularly vulnerable to influences in placental function
such as the UAA procedure, PI (where reduction in oxygen and nutrient delivery typically
results in growth restriction), and LBW13,60–62. As a result, not only are the birth weights
of LBW categorized offspring reduced, but body composition is also altered, as evident by
the reduction in weight/length ratio32,62. An in utero insult such as UAA likely impacts
genetically determined growth differentially. Yet, during post-natal life, a reversal of this
delayed growth trajectory was observed in LBW offspring, where, by young adulthood,
LBW body weights were similar to the NBW group. This pattern of rapid catch-up growth
is a known consequence of asymmetrical growth restriction63,64. More importantly, this
accelerated growth trajectory during the critical postnatal developmental periods have been
implicated in metabolic and endothelial impairments, as well as the development of chronic
diseases such as adulthood diabetes and CVDs29,65,66.
CVDs such as cardiomyopathy are often accompanied by the development of
cardiac hypertrophy. This hypertrophic phenotype is an important marker of deteriorating
cardiac health, and eventually, heart failure4,67. Interestingly, during critical periods of
cardiac disease progression, disturbances in coronary flow can also occur. For example, up
to a 16% reduction in basal coronary blood flow have been observed in patients with
hypertrophic cardiomyopathy20,21. Therefore, we regarded these parameters as essential
clues in recognizing early changes to cardiac health, and valuable predictors of systolic
dysfunction and cardiomyopathy47. Utilizing DCE-CT, we observed that LBW offspring
had a 17% reduction in basal coronary flow compared to the NBW group at 110 days of
age. This reduction in coronary flow may reflect disturbances in myocardial capillaries,
and microvasculature, which are the main determinants of coronary blood flow. It has been
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previously reported that during pathological hypertrophy, capillary density in the left
ventricle is greatly reduced47. This led us to speculate that LBW may be a major risk factor
for CVD development in adulthood via hypertrophic and fibrotic processes. Indeed, by
putdown, histological analyses revealed that the average cardiomyocyte size in LBW
animals were significantly increased compared to NBW animals. Furthermore, LBW
animals also displayed a higher percentage of collagen composition independent of sex,
and an increased mRNA expression of type 1 collagen in females. The enlargement in
cardiomyocytes and the abundance of collagen are hallmarks of a pathological hypertrophy
phenotype, and supports our speculation that reductions in coronary flow determined by
DCE-CT maybe a reflection of its development.
This apparent prenatal programming of cardiac remodeling may have emerged
from the hindered development of cardiomyocytes in utero. A reduction in cardiomyocyte
numbers has been identified as a major consequence of an insufficient in utero
environment, and since proliferation of cardiomyocytes halts in the postnatal period, the
demand for postnatal cardiac growth is therefore fulfilled by hypertrophic growth68,69.
Furthermore, remodeling of the developing heart may be driven by increased vascular bed
resistance in LBW offspring in utero, resulting in an increased mechanical force for
ejection70,71. This chronic increase in ventricular load has been shown to trigger cardiac
remodeling processes that underlie the development of pathological hypertrophy early in
adolescence

71,72

. Together, these underlying factors can be further aggravated by the

increasing demand for growth in a rapid post-natal growth profile, and as a result, rapid
development of CVD may occur. Growth restricted pregnancies have been documented to
result in increased ventricular diameter, intima-media thickness, and altered ventricular

78

shape in children, all indications of an early hypertrophic phenotype73. Altogether, these
results suggests that an adverse in utero environment characterized by insufficient supply
of oxygen and nutrition to meet the adequate growth potential during pregnancy, combined
with the postnatal pressures of catch-up growth underlies the development of pathological
hypertrophy. This in utero programmed alteration in cardiac physiology may very well be
responsible for the vulnerability of LBW offspring to CVD development in later life.
Diets such as the WD during postnatal life can also have major consequences in
cardiac health. Long term consumption of a WD is associated with diabetes, hypertension,
and heart failure 9,57. While these gross abnormalities develop over the course of adulthood,
tissue specific alterations in metabolism develop prior to whole body expression of the
disease states. For example, cardiac IR has been shown to occur prior to that of whole body
IR and more importantly, prior to cardiovascular dysfunction6,44,50. Interestingly, we have
seen that both LBW and postnatal high fat/sugar diet exposure are required to unmask the
consequential effects on glucose homeostasis, and insulin signaling19. Therefore, we
suspect that WD consumption and cardiac IR can exacerbate the consequences of prenatal
programming of CVDs. Despite normal whole body glucose tolerance (K. Dunlop, per
comms), cardiac PET scan demonstrated that WD consumption was associated with a
reduction in basal glucose uptake in the left ventricle, independent of BW. Additionally,
postnatal WD feeding was associated with a reduction in AKT-1 T308 phosphorylation,
with a higher magnitude of reduction in females, despite no changes in AKT-1 S473
phosphorylation. Activation of AKT is an important step in the insulin mediated glucose
uptake pathway, and is normally represented by phosphorylation at both S473 and T30874.
However, reports have suggested that the activity of AKT is more closely correlated with
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T308 phosphorylation, and that concurrent inhibition at both sites is not required for
depression in insulin signaling75–77. This suggests the possibility that glucose transport and
uptake in the left ventricle may have been suppressed by WD consumption via the
inhibition of T308 phosphorylation of AKT-1. Together, these findings suggests that WD
plays a prominent role in the onset of cardiac IR through disruptions in the insulin signaling
pathway. Interestingly, we suspect that the onset of cardiac IR is an early protective
mechanism against cardiac dysfunction. This same idea was also advocated by a study
which demonstrated preserved cardiac functions in insulin resistant high-fat diet fed rats44.
However, with time, a more advanced stage of the disease can unfold, where fatty acid
oxidation – the primary energy source in cardiac metabolism – is disrupted, and may lead
to severe cardiovascular dysfunction78,79. In further support, high-fat diet studies have also
demonstrated that fatty acid oxidation was increased in an early non-hypertrophied
myocardium, but maladapted in a hypertrophied myocardium10,80. Based on these reports,
the diet dependent depression in basal glucose uptake observed in this study suggests that
these animals are in an early stage of CVD progression, with the potential for more severe
cardiovascular related consequences in later life.
Interestingly, WD fed NBW animals also demonstrated high amounts of collagen
in the left ventricle, similar to the levels measured in LBW animals. This is likely the result
of excessive accumulation of ROS from saturated fatty acids present in the WD, which is
linked to extracellular matrix remodeling and fibrosis 79,78. However, since LBW and WD
consumption individually resulted in similar levels of collagen content, this implied that
the combination of LBW and WD did not result in an additive relationship at the age
studied. Similarly, our group’s previous study also discovered that endothelial dependent
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relaxation was blunted in LBW offspring, but again not affected by the secondary insult
from WD29. However, other studies have proposed that IUGR could enhance the harmful
metabolic responses to a high fat diet through IR and adipocyte dysfunctions81. Perhaps the
in utero enhancements of diet induced CVD development processes requires a longer
manifestation period. Thus, further studies on long term impact should be conducted.
Nonetheless, it is clear that the consequences from WD consumption may not be
manifested as rapidly as in utero insults, and may also occur in a different manner. For
example, hypertrophic growth and fibrosis in LBW offspring may have arisen from chronic
increases in vascular bed resistance in utero combined with pressures from rapid postnatal
growth. Meanwhile, consumption of WD is associated with cardiac IR, with multiple
proposed underlying mechanisms, including adipocyte dysfunction, inflammation, and
release of fatty acid metabolites19,82,83. Despite the disassociation between LBW and WD
effects in our study, other reports have demonstrated that growth restricted fetuses are
linked to the development of IR in adulthood. Specifically, during growth restriction, the
limited supply of glucose can lead to the shutdown of the Insulin like Growth Factor (IGF)
system84. However during postnatal life, the abundance in nutrients, and demand for catchup growth results in excessive increases in insulin production, and activation of IGF system
and insulin-like actions, which ultimately, results in adult IR85. Therefore, given that LBW
and WD insults share similar cardiovascular consequences, we expect that with age, these
common consequences of LBW and postnatal WD such as IR and fibrosis will become
exacerbated.
The consequences of poor in utero growth and poor postnatal diets have been
widely accepted to play critical independent roles in the later life development of CVDs.
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Recent work is now beginning to unravel the complex interactions in CVD development
when both these situations occur concurrently. In this current report, we used DCE-CT to
report reductions in coronary blood flow at young adulthood associated with LBW. In
support, molecular results also indicated evidence of cardiac hypertrophy, which likely
contributes to the alterations in blood flow. These findings suggests that abnormal cardiac
development processes at birth may arise from environmental pressures during pregnancy.
This manifests in postnatal life, resulting in the development of key pre-clinical markers of
CVDs. Additionally, the use of PET imaging also highlighted an early indication of altered
cardiac insulin sensitivity, though it was only associated with WD consumption following
weaning. Alterations in cardiac glucose uptake, or insulin sensitivity is also a strong early
indicator of many CVDs, where by young adulthood, WD fed offspring, irrespective of
birthweight, were significantly impacted. Despite the healthy, non-obese, glucose tolerant
phenotype (K. Dunlop, per comms), these changes in the cardiovascular system exposes
the underlying development of severe CVDs. Furthermore, since in utero predisposition
and WD consumption share common consequences such as early indication of cardiac
fibrosis and IR development, we believe that with time, the exacerbated effects of these
two insults will become more apparent. In summary, this study used non-invasive, novel
imaging techniques to detect specific early markers of CVDs, and highlights the need for
additional long term studies on the combined effects of in utero and postnatal insult.
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Chapter 3

3

The Impact of an Adverse Maternal Diet Prior to and During Pregnancy Upon
Young Guinea Pigs Fed a Postnatal Western Diet on the Early Development
of Cardiovascular Diseases.
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3.1 Introduction

Development of cardiovascular diseases (CVD) are typically associated with
unhealthy lifestyle choices such as physical inactivity, smoking, and the consumption of
Westernized Diets (WD)1,2. As the highest cause of mortality in the developed world,
CVDs like cardiomyopathy are a major risk factor to our society. That is before taking into
account the recent revelations in perinatal research, which highlights the contributions of
adverse fetal programming on the development of chronic diseases in adultood3. This
concept of prenatal stress as origins of CVDs and its markers such as myocardial insulin
resistance (IR), and left ventricular hypertrophy have been coined “fetal programming”4–6.
Indeed, previous studies have demonstrated that maternal WD consumption during
pregnancy was associated with a higher risk for developing growth restriction, LBW and
later life chronic diseases in the offspring6–8. Similarly, our previous findings also
demonstrated that postnatal WD feeding could result in disruptions in myocardial glucose
uptake - a sign of IR, and deteriorating cardiac health. Conceivably, the consumption of a
WD during pregnancy may also deny the developing fetus the necessary dietary and
nutritional requirements, therefore providing another means of developing later life
diseases. Compelling evidence have strongly advocated that ongoing consumption of
unhealthy diets in pregnancy and in postnatal life, can further hasten or exacerbate the
progression of chronic diseases in adult life5,6,9,10.
Studies have demonstrated that the onset of severe cardiovascular consequences
such as cardiac dysfunction could result from in utero and postnatal dietary insults11–13.
However, these end-point studies represents a mature disease state, and hence miss the
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preclinical developmental markers which precedes them. For example, the development of
cardiac dysfunction resulting from severe CVDs are often preceded by cardiac remodeling
processes including hypertrophy, and fibrosis in the myocardium14,15. This onset of
pathological hypertrophy occurs in conjunction with a reduction in capillary density, which
is strongly associated with alterations in coronary blood circulation and cardiomyocyte
hypoxia16. Furthermore, reductions in coronary flow reserve – the ratio of stress to basal
coronary flow – which precedes the onset CVDs is an effective pre-clinical indicator of
heart failure17–20.

From a clinical perspective, techniques which can non-invasively

visualize these pre-clinical parameters and predicate later life CVD development are highly
important. An effective predictor of long-term atherosclerotic disease progression appears
to be coronary endothelial and flow function18. However, traditional methods in measuring
coronary flow often requires invasive catheterization21, while molecular studies in animals
again only provides end point results. In the previous chapter, we have demonstrated the
potential of non-invasive imaging in cardiovascular research, therefore we again proposed
the use of Dynamic Contrast Enhanced Computed Tomography (DCE-CT) and Positron
Emission Tomography (PET) as early detection methods of compromised coronary blood
flow and cardiac glucose uptake respectively.
The purpose of this study was to determine whether the consequences of dietary
insult, through all life exposure, and during pregnancy is translated to the next generation.
Specifically, we aimed to investigate if these insults would result in the onset of preclinical
markers of CVDs in the offspring by adulthood. We postulated that maternal WD
consumption prior to and during pregnancy and lactation, combined with offspring
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postnatal WD consumption would result in alterations in coronary blood flow, and cardiac
glucose uptake, both early markers of CVDs, in adulthood.
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3.2 Methods

3.2.1

Animal Model

This study utilized female Dunkin-Hartly guinea pigs (Charles River Laboratories,
Wilmington, MA) which were fed ad libitum from weaning to either a control diet (CD)
(TD:110240, Harlan Laboratories, Madison WI), or a Western Diet (WD) (TD:110239,
Harlan Laboratories, Madison WI) (See Table 2.1). Guinea pigs were housed individually
at 19°C and 30% humidity with 12 hour light-dark cycle. These female guinea pigs were
allowed to breed with male guinea pigs that were fed ad libitum to guinea pig chow
(LabDiet diet 5025: 27% protein, 13% fat, 60% carbohydrates). Sows delivered naturally,
and birth weights of each pup were recorded. Subsequently, these pups were weaned at 15
days of age, and randomly assigned onto either a CD or WD, which formed the four
treatment groups of Maternal CD/ Postnatal CD (MC/CD), Maternal CD/ Postnatal WD
(MC/WD), Maternal WD/ Postnatal CD (MW/CD), and Maternal WD/ Postnatal WD
(MW/WD). Pups were weighed twice a week, and feed intake determined daily out to study
endpoint.

3.2.2

Imaging

Previously, a study had reported that alternations in glucose tolerance associated
with in utero insults occurred at approximately 101 days in a guinea pig model22. Similarly,
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we selected the 110 day as a representative time point at young adulthood to investigate
cardiac health. Additionally, another study also reported onset of IR at 210 days following
high fat diet introduction23. Therefore, a 210 day time point was also selected to investigate
changes which may develop later in adulthood. At the chosen 110 and 210 days of postnatal
life, guinea pigs underwent DCE-CT and PET|. Induction of anesthesia was performed in
an air tight chamber, through which 4-5% isoflurane was administered at a rate of 2L/min.
During both DCE-CT and PET scanning, anesthesia was maintained with a tight fitting
nose cone with 2-3% isoflurane flowing at a rate of 1L/min

3.2.3

Dynamic Contrast Enhanced Computed Tomography (DCE-CT)

This study utilized a GE Healthcare multi-slice CT system (Discovery VCT, GE
Healthcare). Guinea pigs were positioned in the center of the CT scanner. To measure
baseline coronary flow levels, a two phase DCE-CT scan was conducted following an
intravenous injection of 1ml/kg of iodinated contrast (Omnipaque 200mgI/mL) via a pedal
vein catheter at 8 ml/min. In the first phase of the scan, images were acquired continuously
every second for 14.6 seconds. This was immediately followed by the second phase, where
images were acquired every 15 seconds for 200 seconds. For both phases, images were
acquired at a tube voltage of 120 kV, current of 180 mA, and a rotation speed of one
revolution per second. Ten minutes following baseline data acquisition, hyperaemic blood
flow was also recorded by induced cardiac stress. Briefly, dipyridamole (DIP, 0.56mg/kg)
was injected at 0.142 mg/kg of body weight/ minute over four minutes, and a two phase
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DCE-CT scan, similar to the one at baseline was repeated three minutes after infusion of
measurement of hyperaemic blood flow.
DCE-CT images were reconstructed at a 1.25mm slice thickness, and transferred to
an image processing workstation (Advantage Windows 4.0; GE Healthcare, Waukesha,
Wis). Using CT Perfusion 5 program (GE Healthcare, Waukesha, Wis), an arterial input
curve of contrast medium concentration was generated with a region of interest (ROI)
placed in the left ventricle chamber of a slice which showed maximum size of the chamber.
Following which, another ROI was outlined around the contour of the heart in the first
image of the dynamic series of the same slice. Subsequent images which did not conform
to this heart outline were removed from the study as they were mis-registered with the first
image from either breathing or cardiac motion of the animal. Blood flow maps of the
chosen slice was generated with CT Perfusion 5 software (GE Healthcare, Waukesha, Wis).
Myocardial blood flow was calculated as the mean pixel value in a ROI placed in the
inferior wall of the left ventricle. This process was repeated for images acquired following
dipyridamole injection, and coronary reserve was calculated as the ratio of DIP to basal
coronary flow.

3.2.4

Positron Emission Tomography

Guinea pigs were anaesthetized in an air tight box with 4-5% isoflurane at 2L/min,
and injected with ~25kBq/kg (0.2-0.3mL) of [18F] - fluoro-deoxy-glucose ([18F] FDG) via
the pedal vein. Animals were allowed to recover for 40 minutes in their cage behind a lead
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brick shield. Animals were then anaesthetized again transferred onto micro-PET scanner
(GE eXpore Vista DR, GE Healthcare, Waukesha, Wis), and maintained at the
anaesthetized state with 2.5-3% isoflurane at 1L/min in a nose cone. Images of the heart
region were acquired by a 20 minute emission. Following correction for scatter and random
coincidences, images were reconstructed into sixty 0.78mm thick slices. The reconstructed
images were analyzed using an in-house MATLAB program (MathWorkds Inc., MA,
USA). Two ROIs were drawn in each slice in which the left ventricle was visible. One
outlining the epicardial surface, and the other one the endocardial surface of the left
ventricle. The difference in the total counts was divided by the difference in volume of the
ROIs to arrive at the average count in the myocardium. This average was converted to
activity (Bq) using a sensitivity calibration factor determined from routine quality
assurance of the scanner. The image derived activities from all left ventricle slices were
averaged together to calculate myocardial activity. Measurements of Standardized Uptake
Value (SUV) was calculated as:

𝑆𝑈𝑉 =

3.2.5

𝑀𝑦𝑜𝑐𝑎𝑟𝑑𝑖𝑎𝑙 𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦
𝐼𝑛𝑗𝑒𝑐𝑡𝑒𝑑 𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦 ⁄𝐵𝑜𝑑𝑦 𝑊𝑒𝑖𝑔ℎ𝑡

(1)

Tissue Collection

At approximately postnatal day 250, animals were fasted overnight, and sacrificed
by CO2 inhalation23. The heart was removed, trimmed of connective tissue, carefully
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separated into left or right ventricle, weighed and snaps frozen in liquid nitrogen for RNA
and protein analysis.

3.2.6

Quantitative Real-Time PCR

Frozen tissues were homogenized in Trizol® (Invitrogen Life Technologies Co.,
Burlington, ON) with mortar and pestle, and 200 µL of chloroform was added. The
mixtures were centrifuged at 12,000g for 15 minutes at 4°C, and the separated aqueous
phase was transferred to new RNAse-free tube, and mixed with 500 µL of isopropyl
alcohol. RNA precipitate were obtained by an additional centrifugation at 12,000g for 10
minutes at 4°C, and three washes with 75% ethanol at 7500g for 5 minutes. The resulting
RNA pellet was reconstituted in RNAase free diethylpyrocarbonate water, and yield
quantity and quality (A260/A280 ration) of RNA was determined with NanoDrop 2000
UV-Vis Spectrophotometer (Thermo Scientific, Waltham MA, US). To obtain
complementary DNA, 4µg of RNA were reverse transcribed with Moloney Murine
Leukemia Virus Reverse Transcriptase (Invitrogen Life Technologies Co., Burlington
ON). Measurement of gene expressions were completed by Real-time Quantitative
Polymerase Chain Reaction (qPCR) in a triplicate manner using a Bio-Rad CFX384 real
time PCR detector (Bio-Rad Laboratories Mississauga, ON). QPCR reactions were
performed with a denature temperature of 95°C, annealing temperature of 59.5°C and
elongation temperature of 72°C for 39 cycles. The 2-ΔCT method was used for analysis, with
β-Actin as the housekeeping gene 24. Primer and genes used are shown in Appendix A.
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3.2.7

Western Blot

Flash frozen left ventricle tissues were individually pulverized and homogenized in
RIPA lysis buffer (50 mM Tris-HCl, NP-40 1%, Na-deoxycholate 0.25%, 1mM EDTA,
150 mM NaCl, 50 mM NAF, 1mM NaV, 25 mM β-glycerophosphate, pH 7.4) with
protease and phosphatase inhibitor. Homogenates were centrifuged at 10,000g for 15
minutes at 4°C. The resulting supernatant were isolated as protein preparations, and
quantified with DC™ Protein Assay Kit (Bio-Rad Laboratories, Mississauga, ON). Using
6% Bis-Tris gels, 30 µg of protein were separated by size, and then transferred on to
nitrocellulose membranes. Each membrane was stained with Amido Black stain, and
imaged with VersaDoc Imaging System (Bio-Rad Laboratories Mississauga, ON) as
house-keeping. The membranes were then washed and blocked overnight with 5% bovine
serum albumin at 4°C. Blots were then probed with AKT-1 (Cell Signaling® #4691,
1:1000), pAKT Serine 473 (Cell Signaling® #9271, 1:1000), pAKT Threonine 308 (Cell
Signaling® #9275, 1:1000), and monoclonal horseradish peroxidase-conjugated β-actin
(Sigma-Aldrich #A3854, 1:50000) diluted in 5% bovine serum albumin in Tris-buffered
saline – Tween 20 (0.01%) for 1 hour at room temperature. After washing, a horseradish
peroxidase conjugated goat anti-rabbit IgG (Cell Signaling® #7074, 1:1000) secondary
antibody diluted in 5% bovine serum albumin in Tris-buffered saline – Tween 20 (0.01%)
was used to incubate blots at room temperature for 1 hour. Immunoreactive bands were
detected using Luminata Forte Western HRP Substrate chemi-luminescence (EMD
Millipore, Darmstadt, Germany), and imaged with VersaDoc Imaging System (Bio-Rad
Laboratories Mississauga, ON). Abundance of protein were calculated using densitometry
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values (arbitrary units) determined with ImageLab software (Bio-Rad Laboratories,
Mississauga, ON), and expressed relative to Amido Black Staining.

3.2.8

Statistical Analysis

Statistical Analysis was performed with SPSS software (SPSS v22.0, Chicago, IL,
USA). A mixed model ANOVA analysis was used to determine significant differences
(p<0.05) from age, maternal diet, and postnatal diet. If significant differences or
interactions were determined, student t-tests were used to for post-hoc analysis of
differences between groups.
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3.3 Results

3.3.1

Maternal WD Did Not Result in LBW, or Rapid Catch-Up Growth

We aimed to determine if the consequences of dietary insult, through all life
exposure, and during pregnancy is translated to the next generation. Offspring from WD
fed mothers did not demonstrate any reductions in birth weight, or weight/length ratio
compared to those born from CD fed mothers (Figure 3.1.). Furthermore, offspring growth,
caloric intake, and food efficiencies from weaning to postnatal day 50, and postnatal day
50 to 110 were not significantly different between the four groups (Figure 3.2). As a result,
no initial signs of growth restriction, or the rapid postnatal catch-up growth was observed
from maternal WD pregnancies when placed on a postnatal CD or WD.
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Figure 3.1 Birth Characteristics A) Birth weight and B) Weight/length of guinea pig
pups. Pups were from either CD or WD fed mother bred with a chow fed control male. No
significant changes in birth weight or weight/length ratio were observed due to maternal
diet. N= 11 for offspring from CD mothers, and N=12 for offspring from WD fed mothers.
Box represents Mean and SEM, while whiskers represents Max and Min values. Statistical
significance was determined by student’s t-test.
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Figure 3.2 Post-Weaning Growth Characteristics. A) Growth rate, grams gained per
day. B) Calories consumed per day. C) Food efficiency, gram gained per day/calories
consumed per day from weaning to postnatal 50 days, and postnatal 50 days to 110 days
was determined. All data sets are presented by mean ± standard error, and no significant
changes were observed between all four treatment groups. N=8 (MC/CD), 3 (MC/WD), 6
(MW/CD), and 4 (MW/WD). Statistical significance was determined by two-way
ANOVA.
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3.3.2

Basal and Reserve Coronary Blood Flow Not Affected by Maternal or
Postnatal WD Consumption

Alterations in basal coronary blood flow have been reported to precede heart failure
and increases in severity with the onset of cardiomyopathy19,20,25,26.Therefore, in this study,
baseline coronary blood flow levels were assessed at postnatal 110 days, and 210 days by
DCE-CT as a marker for CVD development. Coronary blood flow in the inferior wall of
the left ventricle were compared between maternal diet, postnatal diet, and age factors.
However, basal coronary blood flow appeared to be consistent across all treatment groups
(Figure 3.3).
Reductions in coronary reserve are also strong indicators of cardiomyopathy, and
systolic dysfunction, particularly in situations of low peripheral arterial resistance where
basal coronary flow could appear normal17,25,27. However, despite a dipyridamole
challenge, an average 69% coronary flow increase was observed across all four treatment
groups (Figure 3.4). Thus, it appears that maternal diet, and postnatal diet do not result in
changes in coronary reserve as determined by non-invasive imaging at the ages examined.
Additionally, this study also investigated the mRNA expression of genes which may
provide insight into possible fibrotic processes in the left ventricle. These included
Collagen 1, 3, and matrix metalloproteinase-2 (MMP-2). Interestingly, the expression of
these genes were also not altered as a result of diets in maternal or postnatal period.
Collectively, these findings suggests that at the ages studied, both maternal and postnatal
WD consumption did not result in disruptions in coronary circulation and indicators of
pathological hypertrophy.
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Figure 3.3 Basal Coronary Blood Flow at 110 and 210 Days. Basal blood flow in the
inferior wall of left ventricle at A) 110 and B) 210 days of age were determined by CT
Perfusion 5. No statistical differences were determined between groups. At 110 days N=11
(MC/CD), 3 (MC/WD), 9 (MW/CD), and 4 (MW/WD). At 210 days N=7 (MC/CD), 1
(MC/WD), 6 (MW/CD), and 2 (MW/WD). Statistical analyses were performed using a
two-way ANOVA.
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Figure 3.4 Coronary Reserve. Mean coronary blood flow was determined prior to after
dipyridamole stress at 110 days scan. Coronary reserve was calculated as ratio of stress to
basal coronary flow. No significant differences were observed between the treatment
groups. N= 7 (MC/CD), 8 (MW/CD), and 3 (MW/WD). Statistical analyses were
performed using a two-way ANOVA.
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3.3.3

Postnatal WD Consumption Resulting in Reduced Glucose Uptake

To assess cardiac glucose uptake, as a proxy indicator for insulin sensitivity, PET
was utilized. Previous studies have reported that during the developmental phase of CVDs,
IR also develops, and is believed to be a protective mechanism against further cardiac
injury28–30. Although an interaction between maternal diet and post-natal diet was observed,
this was not statistically significant (Figure 3.5, p=0.056). However, this trend suggested
that maternal diet’s effects were not consistent between the different postnatal diets.
Specifically, a MC/WD mismatch resulted in a 30% decrease in glucose uptake compared
to MC/CD group.
Underlying the changes in cardiac glucose uptake is insulin sensitivity. The insulin
signaling pathway is primarily responsible for the insulin mediate uptake of glucose
through glucose transporters in the heart, and is primarily regulated by series of
phosphorylation steps31–33. Specifically, we investigated the protein expression of Protein
Kinase B (AKT) Threonine 308, Serine 473, and Insulin Receptor Substrate 1 (IRS-1). The
expression of AKT-1 T308 demonstrated a significant decrease as a result of postnatal
feeding in both MC and MW groups (Figure 3.6). Associated markers of insulin signaling,
IRS-1 and Ser473 AKT-1 were however, unaltered (Figure 3.7).
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Figure 3.5 Glucose Uptake Determined by PET. Standard Uptake Value of the left
ventricle acquired by PET at A) 110 and B) 210 days. Data presented as Mean ± Standard
Error. No statistical significance was observed between groups at both time point. At 110
days N= 11 (MC/CD), 3 (MC/WD), 6 (MW/CD), and 5 (MW/WD). At 210 days N= 8
(MC/CD), 3 (MC/WD), and 3 (MW/WD). Box represents Mean and SEM, while whiskers
represents Max and Min values. Statistical significance was determined by a repeated
measures two-way ANOVA. ANOVA table presented in Appendix I
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Figure 3.6 Protein Expression of pAKT (T308) at Putdown. Expression of pAKT
(T308) relative to total AKT-1 protein in the left ventricle at 240 days of age. *p<0.05.
N=11 for CD, and N=9 for WD groups. Statistical significance was first determined by
two-way ANOVA, and further analyzed by student’s t-test. Box represents Mean and SEM,
while whiskers represents Max and Min values. ANOVA table presented in Appendix J
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Figure 3.7 Protein Expression of pIRS (S307) and pAKT (S473) at Putdown. Protein
expression of A) Serine 307 pIRS relative to total IRS protein, and B) Serine 473 pAKT
relative to total AKT-1 protein expression No significant differences were observed. N=7
(MC/CD), 4 (MC/WD), 4 (MW/CD), and 5 (MW/WD). Statistical significance was
examined by two-way ANOVA
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3.4 Discussion

This current study explored the consequences of WD, particularly its influences in
utero, and in postnatal life on the development of CVDs in offspring as they mature into
adulthood. Interestingly, maternal WD consumption from weaning through maturation and
pregnancy did not appear to aggravate cardiac function in the next generation, which are
either control fed or further challenged with a postnatal WD. We believe that due to in
utero adaptation to maternal diets, maternal WD may not have prominent or direct effects
on offspring health at the age studied. Quite possibly, maternal obesity, or further postnatal
diet challenge is necessary to fully elucidate the programming effects of a maternal WD34.
However, we can speculate from related studies that given maternal WD’s effects on other
organ systems, and its long term predisposition for further postnatal insult, it can impact
cardiovascular function later in adulthood.
In contrast to the Uterine Artery Ablation (UAA) model used in the previous
chapter, a maternal WD introduces an abundance of carbohydrates, and saturated fatty
acids. We have already determined that restriction in fetal nutrients is associated with
LBW, and by late adulthood, left ventricular hypertrophy like symptoms. Other studies
have also determined that LBW (induced by maternal hypoxia) and other extreme prenatal
insults such as maternal obesity, resulting in large birth weight, and poor postnatal
outcomes when challenged with an adverse postnatal high fat diet insult9,35,36. Consumption
of WD in postnatal life is known to result in the development of chronic diseases such as
CVD, even in individuals born of NBW37,38. Naturally, we are interested in whether
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prolonged exposure to WD, particularly during in utero period, can accelerate or
exacerbate these processes.
We observed that lifelong maternal WD feeding did not yield LBW pups. Studies
in non-human primates reported that maternal consumption of a high fat diets increases the
risks of placental inflammation, and stillbirth, and more importantly, it was also associated
with a reduction in uterine artery blood flow39. This revelation is analogous to the UAA
model, and we predicted that a lifelong a maternal WD would result in similar
consequences, however that was not the case. Although high energy diet consumption and
obesity during pregnancy are associated with IUGR40, fetal overgrowth and large-forgestational age is not uncommon41,42. In support, studies have suggested that prenatal
programming of IR, and birthweight alterations may be more associated with maternal
adiposity than dietary fat34. However, in this study, despite chronic WD feeding in
mothers, they were by no means overweight, which perhaps provides an explanation for
the lack of the extreme birth weight phenotypes in the offspring. Furthermore, offspring of
postnatal growth and food efficiencies were similar across the treatment groups, therefore
a postnatal catch-up growth profile commonly associated with development of chronic
diseases was not apparent. However, adverse prenatal environment can still possibly give
rise to adult chronic diseases, such as obesity, IR, and cardiac dysfunction later in
adulthood9,35,39,43,44. As a result, we are interested in the effects of postnatal WD
consumption, and how they might play a role in the development of chronic diseases in the
offspring, particularly in combination with chronic maternal WD insult.
In the build-up to many CVDs such as cardiomyopathy, disturbances in coronary
circulation can occur, providing a useful predictor of cardiac dysfunction45,46. Utilizing
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DCE-CT, baseline coronary flow in the left ventricle microvasculature at postnatal day 110
and 210 were measured. Interestingly, no alterations in coronary blood flow was observed
between the groups. However, baseline coronary flow may not be a definitive indicator of
coronary complications. This is particularly important, as basal coronary blood flow can
still be maintained at normal levels by reducing distal arterial resistance, therefore masking
the disturbances in coronary physiology27. However, when challenged, the ratio of stressed
to basal blood flow, or the coronary reserve of compromised hearts is diminished27.
Inducing stress through dipyridamole creates a discrepancy between the blood flow of
stenosed and normal coronary arteries, which can provide further insight on the changes of
left ventricular hemodynamics. Intriguingly, despite a dipyridamole challenge, coronary
reserve was similar across all four treatment groups. This observation was akin with our
previous findings, where postnatal WD feeding alone was not associated with coronary
disruptions and markers of left ventricular hypertrophy. This study draws an additional
revelation in that offspring of maternal WD feeding also did not display hemodynamic
alterations in the left ventricle.
Maternal high-fat feeding have been strongly associated with the development
metabolic diseases development in later life, with cardiac IR as a strong indicator9,22,47.
Furthermore, in conjunction with a post-natal WD challenge, development of hypertension,
and heart failure can be further exacerbated48. A previous study have reported
cardiomyocyte glucose intolerance resulting from high-fat diet feeding23 Therefore, early
diagnosis of pre-clinical markers such as cardiac IR is important. The PET technology
opens up the possibility of detecting changes in glucose uptake in the left ventricle and
identifying at risk individuals in a non-invasively manner. In this chapter, no statistical
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differences in left ventricular glucose uptake was found, yet a strong interaction between
maternal diet and postnatal diet may be at play. Where, offspring of a CD fed mother
displayed lower glucose uptake when given a postnatal WD compared to offspring born of
WD fed mothers that were also fed the same postnatal WD. In comparison, this pattern was
reversed with postnatal CD, where maternal CD offspring displayed higher glucose uptake
compared to offspring from a WD fed mother. Furthermore, molecular analyses revealed
that a postnatal WD alone was associated with a reduced protein expression of
phosphorylated T308. Typically, the phosphorylation of T308 is an important step in the
insulin signaling pathway, which ultimately translates to the translocation of glucose
transporters to the membrane49. This is yet another piece of evidence which suggests that
at adulthood, these offspring displayed reduced glucose uptake and associated IR in the
heart as a result of WD consumption in postnatal life. This is also in alignment with our
results in the LBW model, where changes in cardiac insulin sensitivity are largely
determined by postnatal diet.
These changes in cardiac glucose uptake also highlights in utero programming at
work, where the prenatal environment is largely influential on the offspring’s adaptability
to the postnatal environment. Specifically the mismatch between maternal and postnatal
diet introduces susceptibilities in cardiac glucose uptake. The fetus is programmed to adapt
its growth and developmental profiles during adverse uterine environments to ensure its
survival in a similar postnatal environment. This hypothesis harkens back to the studies on
Dutch hunger winter, and the Leningrad Siege, which clearly demonstrates how glucose
tolerance and other metabolic diseases are associated with a mismatch of prenatal and
postnatal environments50–52. In support, a study has reported that in response to maternal
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high fat diet, offspring development of endothelial dysfunction in adulthood was prevented
if offspring were raised on the same diet53. This however, is not to say that offspring born
of a WD pregnancy should continue to indulge on the unhealthy diets, as ultimately it did
not prevent the development of hypertension, and may pose a higher risk in the long term53.
Additionally, this inferred that postnatal dietary factors might play a more influential role
in the outcome of cardiac insulin sensitivity at the young adult age. It is possible that
maternal dietary effects may not yet be discernable at the young ages studied. A non-human
primate study reported that offspring of chronic maternal high-fat diet animals that
underwent a diet reversal just prior to breeding retained normal acetylation of histone H3,
where its alteration is commonly accompanied by nonalcoholic fatty liver diseases54.
Maternal WD effects may not be prominent at first, and may require an additional insult,
such as a postnatal WD, to be fully elucidated. Although studies on maternal diet reversal
and CVD developments are lacking, we can speculate that the associated effects of a
maternal WD requires long term exposure, and predisposes the offspring to further insult
from a postnatal WD challenge5,10.
Although chronic maternal WD consumption did not yield the same hallmarks of
hypertrophic cardiomyopathy observed in the LBW model. Previous studies have reported
the susceptibility of a pregnancy marred by a high-fat diet to the development of chronic
diseases such as CVDs. For example, offspring of chronic maternal high-fat feeding in rats
displays increased body weight, and insulin insensitivity by adulthood6. Additionally, these
changes appears to be highly heritable, where it has been observed to persist onwards to
the second generation, and are believed to be a result of changes in epigenetics 55. At the
cardiovascular level, offspring of high-fat fed moms are also associated with endothelial
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dysfunction, and are moderately exacerbated by a postnatal high-fat diet consumption56.
Interestingly, endothelial function appears to improve when offspring are switched to a
control diet, further supporting the notion that postnatal dietary patterns may be more
detrimental to cardiac health56. Comparatively, in this current study, alterations in coronary
circulation were not observed even in adulthood. A possible explanation is that the onset
of CVDs may not occur until later in adulthood. In support, epidemiological studies in
humans highlighted the increased prevalence of CVD development and fatalities in men
were associated with high saturated fatty acid consumption. However, the onset of these
fatal CVDs tend to be in middle age at approximately ~55 years old, where early age
development is categorized as <70 years of age57–60. Therefore we must consider the
possibility that the onset of these complications in the guinea pigs may be well into middle
to late adulthood.
Although poor maternal diet may not appear to play a direct role on CVD
development in offspring at the age studied, we speculate that the offspring’s predisposition
for further insult from postnatal diets is a major risk factor in long term cardiac health.
Previous studies with chronic maternal high-fat feeding have demonstrated severe
consequences in other organ systems by adulthood in the offspring. For instance, maternal
high-fat diet exposure has been linked to development of non-alcoholic liver disease, beta
cell dysfunction and obesity in offspring6,55,61,62. Although maternal WD consumption may
not be a primary influence on later life cardiovascular outcome, the onset of obesity,
diabetes and diseases of other organ systems may impact cardiac function overall, leading
to the emergence of CVDs later in adulthood63,64. Furthermore, chronic exposure to WD in
postnatal life is also associated with the development of similar complications such as IR
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and obesity. We speculate that when combined with the aforementioned maternal WD
effects, severe cardiovascular complications may arise with age. Therefore, the long term
implications of a maternal WD on CVD development should be further investigated in
future studies.
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4.1

Summary

Since Forsdahl and Barker put forth the idea of Developmental Origins of Health
and Disease, many have started to recognize the importance of in utero environments on
the onset of adult diseases. This hypothesis, now further expanded, suggests that the
development of chronic metabolic diseases in later life are the result of fetal programming
mechanisms during critical periods of in utero environment1–3. In particular, a suboptimal
in utero environment, resulting in Low Birth Weight (LBW), and an altered postnatal
growth profile is strongly believed to increase the risk of developing chronic diseases such
as Cardiovascular Diseases (CVDs) in later life1,4. These adverse in utero environments,
can be a result of placental insufficiencies (PI), where the inability to provide the required
oxygen and nutrient supply to the fetus induces a state of growth restriction. In contrast to
a restrictive insult, adverse in utero environments can also arise from excessive maternal
consumption of unhealthy diets such as a Western Diet (WD) through life and pregnancy.
Alarmingly, recent evidence have also suggested that postnatal insults such as the
consumption of WD can further exacerbate the abnormal growth patterns resulting from in
utero insults5. Given the increasing prevalence of WD, its exposure to individuals of an
adverse in utero environment may enhance the detrimental consequences of the growth
restricted developmental profile. However, the mechanisms and relationships in the
combination of prenatal and postnatal factors on the development of chronic diseases are
still unknown.
Of the many non-communicable diseases associated with fetal programming, CVD
distinguishes itself with the highest mortality rate. In 2008, approximately 17.3 million
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people worldwide died from complications related to CVDs, and this number is expected
to rise in the future6,7. Prior to the onset of severe functional phenotypes of CVDs, disease
progression in the myocardium is often marked by cardiac IR, and pre-clinical markers
such as hypertrophy, as well as alterations in coronary circulation8–12. It is likely that the
development of CVDs may stem from the in utero period, and further hampered by
unhealthy diet consumption. Given the severity of the consequences, such as systolic
dysfunction, heart failure, and ultimately death, it is therefore crucial to investigate possible
diagnostic techniques which could detect these early pre-clinical markers of CVDs.
In Chapter 2, we investigated the associated effects of low birth weight (LBW)
resulting from a restrictive in utero environment and postnatal exposure to WD on the
potential for CVD development in adulthood. We postulated that LBW, and WD
consumption combined would result in the development of early pre-clinical markers of
CVDs. Our findings demonstrated that LBW offspring displayed a rapid catch up growth
profile shortly after birth. This accelerated growth trajectory has been implicated as an
underlying factor in the manifestation of chronic diseases such as CVD13–15. Indeed, using
Dynamic Contrast Enhanced Computed Tomography (DCE-CT), this study also
highlighted that this accelerated growth in LBW animals was associated with a reduction
in basal coronary blood flow at postnatal day 110. Moreover accompanying these
alterations in coronary flow was histological evidence of pathological hypertrophy,
including cardiomyocyte enlargement, and fibrosis. However these changes were not
associated with the postnatal consumption of WD. In comparison, WD consumption was
associated with reductions in left ventricular glucose uptake, as indicated by Positron
Emission Tomography (PET). This was also supported by a decreased protein activation
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of AKT-1, therefore possibly contributing to a state of cardiac IR. While in utero
environment and WD consumption independently displayed different components of
compromised cardiac health, their combination however, did not appeared to result in an
exacerbated effect at the ages studied.
In Chapter 3, we expanded our experimental focus on chronic maternal WD
consumption as means of prenatal insult. Maternal WD consumption have been reported
to trigger placental inflammation, and disruptions in placental hemodynamics, which is
also associated with a higher frequency of stillbirths, and prenatal complications16,17.
Furthermore, this unhealthy maternal dietary pattern is associated with the development of
cardiovascular complications such as endothelial dysfunction, hypertension, and IR in the
offspring18–20. Of additional concern is the possibility that the vulnerability induced by an
in utero exposure to WD can be aggravated by a postnatal consumption of the same
unhealthy WD18. However, detailed studies investigating their combined effects on CVDs
are still lacking. In this chapter, we demonstrated that basal coronary flow and coronary
reserve following a dipyridamole challenge were not significantly altered from either
maternal or postnatal WD feeding. PET studies however indicated a strong trend which
suggested that maternal WD may have differential effects on offspring cardiac glucose
uptake depending on the type of postnatal diet consumed. Specifically, this highlights the
effects of a mismatched in utero and postnatal environment, where reductions in cardiac
glucose uptake appears to be more severe in maternal control diet to WD group than
maternal WD to WD group. Although maternal WD’s effects on cardiac health may not
yet be discernable at the ages studied, this study further supported our observation in
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Chapter 2, where postnatal WD consumption is linked to cardiac glucose uptake
reductions, which are suggestive of IR.
In summary, these studies provide evidence for in utero programming of CVDs in
adulthood. In particular, the growth restriction and LBW insult appear to have significant
consequences in the early development of pathological hypertrophy. Moreover, both
studies demonstrated the impact of postnatal WD consumption on the onset of markers of
CVDs in early adulthood. Offspring of chronic maternal WD treatment appears to be free
of the pre-clinical markers of CVDs at the ages studied. However, it is certainly possible
that with age, a postnatal insult can unmask these in utero programmed risks as observed
in reports of HFD, and IUGR interactive studies21. Lastly, although offspring appear
healthy and non-obese while maintaining whole body glucose tolerance (K. Dunlop, per
comms), important preclinical markers of CVDs such as disruptions in coronary flow and
cardiac glucose uptake are present. A key significance of this study, is the applicability of
imaging modalities, which effectively and non-invasively highlight these key
developmental markers of CVD prior to the onset of a disease phenotype.

131

4.2 Speculations

Adverse in utero environments are known risks for the development of heart diseases, such
as cardiomyopathy in later life4,22. This disease of the myocardium may have its origins in
utero due to the unfavourable conditions during cardiovascular development. For example,
a common cause of growth restriction and LBW is placental insufficiency, where the
placenta fails to provide the required oxygen and nutritional needs of the fetus 23. PI can
also induce an increase in placental vascular bed resistance, as a result, fetal hearts must
overcome this increased mechanical force for ejection, thereby creating pressure
overload24,25. This complication predisposes the offspring to the development of
hypertrophy, as concentric hypertrophy is induced by chronic increases in ventricular
pressure26,27. Since this onset of pressure overload occurs in such an early stage during fetal
development, it explains the early presence of left ventricular hypertrophy in LBW
offspring. Moreover, in utero complications during fetal cardiac development can also
hinder cardiac growth, resulting in a reduction in cardiomyocyte number at birth22.
However, the heart is a post-mitotic organ, therefore postnatal growth is dependent on
hypertrophy, or proliferation of non-myocytes22,28. This is further exacerbated by a
postnatal catch-up growth profile that puts additional pressure for rapid cardiac growth.
When the postnatal heart reaches its capacity for hypertrophic growth, further growth will
occur through the deposition of extracellular matrix, therefore beginning the process of
cardiac fibrosis29. This onset of pathological hypertrophy, characterized by fibrosis, can
then lead to severe functional consequences such as cardiac dysfunction30. In our study the
development of hypertrophy and fibrosis were also accompanied by reductions in basal
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coronary flow. Interestingly, since hypoxia during in utero restriction is a stimulus for
coronary vascularization, why is it that our study observed the opposite31? Other studies
have supported our observation, where maternal restriction was not associated with any
increases in coronary vascularization29. Perhaps this can be explained by an associated
effect of hypertrophy and fibrosis, which is the reduction in coronary capillary density32.
These mechanisms are likely what underlie the presence of pathological hypertrophy and
reductions in coronary blood flow in the LBW offspring. However, these were not present
in offspring from the chronic maternal WD model. Although a maternal WD insult may
share similarities with a growth restriction insult, it can result in different outcomes
including LBW and large birthweight18,33,34. Furthermore, its effects on postnatal health
can easily be reversed35. This led us to believe that maternal WD’s effects on offspring
CVD development may be indirect. This is further supported by the fact that maternal WD
offspring did not demonstrate signs of LBW, or the rapid catch-up growth profile that is
usually associated with chronic diseases development in later life.
Similarly, the development of cardiac IR is another pre-clinical marker of many
CVDs11,12. This state of IR, accompanied by a greater demand on fatty acid oxidation as a
fuel source during high-fat feeding can be seen as a protective mechanism against cardiac
dysfunction36. This state of IR can be attributed to the high levels of saturated fatty acids
present in the WD. For example, high levels of saturated fatty acids have been known to
increase the secretion of inflammatory cytokines which impair insulin sensitivity in skeletal
muscle cells37,38. More importantly, saturated fatty acids can also reduce the activity of
peroxisome proliferator-activated receptor gamma coactivator 1- alpha (PGC-1α),
resulting in a reduction in oxidative phosphorylation and insulin-stimulated glucose
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uptake39. Eventually, the onset of severe CVDs occurs when fatty acid oxidation is
maladapted40–42. For example, studies have reported that the expression of peroxisome
proliferator-activated receptor alpha (PPAR-α) – an important activator of fatty oxidation
-

is reduced, while glucose metabolism was increased in rats with pathological

hypertrophy42,43. The accumulation of saturated fatty acids, and its harmful by-products
such as reactive oxygen species (ROS), diacylglycerols (DAG), and ceramide may result
in the onset of fibrosis, and cardiac dysfunction44–47. Our present findings appeared
consistent with these reports, where a postnatal WD depression in basal glucose uptake
was observed. Additionally, early indication of fibrosis was also present in WD fed animals
in chapter 2. This purported that the WD fed guinea pigs, with the reductions in glucose
uptake, likely indicates an early stage of CVD development, with severe cardiovascular
related consequences in later life.
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4.3 Potential Limitations and Future Improvements

Given the ambitious scope, and detail of this study, there are certainly some
limitations that must be addressed. Firstly, this study only chose to examine the pre-clinical
parameters with non-invasively imaging at three different time points, 50, 110, and 210
days. These ages were strategically selected based on a previous study which demonstrate
that the onset of IR, a key marker of metabolic disease development in guinea pigs occurred
around 101 days48. However, they could not fully encompass the early developmental
period in guinea pig adolescence, nor later in adulthood where CVDs typically occur.
Future studies should introduce additional scanning time points to fully assess the
progression of CVD development. In particular, future studies should also focus on the
later life in utero induced multi-organ failure and its relation to CVD development to
ascertain the developmental implications of in utero insults. Studies should also introduce
molecular analysis immediately following scanning to further strengthen the findings of
the non-invasive imaging techniques.
Secondly, non-invasive assessment of coronary blood flow using DCE-CT in a
small animal model have many physical limitations. For example, the rapid heart rate, and
breathing of guinea pigs introduces motion in the generation of blood flow maps. Although
our study compensated for motion with the removal images where the heart shape was not
consistent, this method was not perfect. A solution to this problem is to intubate the animals
during the scanning procedure. However this would induce further stress to the animal.
Future imaging studies should investigate techniques which can fully translate the use of
clinical DCE-CT on small animal research. Despite this, the significance of DCE-CT for
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the detection of preliminary clinical markers should not be ignored. Many of these
limitations do not apply to human subjects – the intended subject of these imaging
modalities– where it has been extensively been used for the study of coronary
circulation49,50.
Another limitation in chapter 2 was that coronary flow was determined at a basal
state, and therefore was not a definitive indicator of coronary complications. Basal
coronary blood flow can be maintained at normal levels by reducing distal arterial
resistance, therefore masking the disturbances in coronary physiology51. However, when
under stress, the coronary reserve - the ratio of increase in coronary flow from stress to
basal levels - of these compromised hearts are diminished51. Therefore, in future studies,
coronary reserve of the LBW model must be examined similar to chapter 3. Moreover, we
have speculated that the onset of hypertrophy and fibrosis underlies the reductions in
coronary blood flow due to a reduction in capillary density32. Therefore, in addition to
histological analysis on cardiomyocyte enlargement, and collagen deposition, future
studies should also investigate ventricular capillary density. This could further strengthen
and ascertain the relationship between in utero insult and coronary vascularization during
CVD development.
Thirdly, the in vivo assessments of glucose uptake by PET were performed under
basal conditions, as opposed to an insulin stimulated dynamic assessment. Similarly the
final tissue collection for molecular analysis were also performed under fasted states in
basal conditions. Measurement of glucose uptake under insulin stimulated situations could
further strengthen our claim of changing insulin sensitivity, given this approach would
demonstrate the implications of the disruptions in the insulin signaling pathway. Therefore
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future [18F] FDG-PET studies should be conducted following insulin administration to
determine the cardiovascular response to insulin. Previous studies which utilized a
hyperinsulinemic clamp prior to [18F] FDG PET clearly demonstrated decreases in cardiac
and skeletal glucose uptake that were associated with insulin resistance36,52,53. Similarly,
tissue collection immediately following insulin injection would also allow us to investigate
the changes in the insulin signaling pathway in response to insulin, and provide further
support of an insulin resistant state.
Lastly, is the limitation in the characterization of a late stage severe CVD. In this
study, we proposed that the pre-clinical markers such as coronary blood flow reductions,
cardiac IR, and hypertrophy are precursors to a more severe phenotype of CVD. Indeed
studies have demonstrated that these parameters have been used to effectively predict the
onset of severe complications such as cardiac dysfunction, and death8,9,54–58. However, this
study is limited in that a severe diseased phenotype was not characterized. Future studies
should investigate an endpoint result from the prenatal and dietary insults, such as the onset
of severe cardiac dysfunction. We propose the use of more traditional imaging systems
such as echocardiography, where the measurement of ejection fraction is a useful tool in
the characterization of deteriorating cardiac function59.
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4.4 Conclusions

This present study highlights the implications of an in utero insult, and a postnatal
WD insult on the development of early preliminary clinical markers of CVD. Despite the
healthy, non-obese, and glucose tolerant phenotype, we believe that the changes in the
cardiovascular system exposes the underlying development of severe cardiovascular
complications. Abnormal cardiac development processes may arise from prenatal insults,
and the rapid catch-up growth profile. These inherent risks manifest themselves, and result
in the onset of early development of pre-clinical markers of CVD such as hypertrophy, and
coronary circulation alterations. Furthermore, our categorization of LBW based on the 25th
percentile also inferred that there are potentially many at risk individuals outside of the
clinically defined 10th percentile cutoff. This further supports the idea that offspring that
have undergone a reprogramming event due to sub-optimal in utero conditions may not be
fully reflected by the clinical birthweight cutoff at 10th percentile60,61. Interestingly,
maternal WD did not appear to play a direct role in the development of CVDs. However,
postnatal WD consumption resulted in alterations in cardiac glucose uptake, again
indicative of eventual CVD development. Studies in our group, and other reports have
demonstrated that in utero insults such as LBW, or a chronic maternal high-fat diet were
associated with non-alcoholic liver disease, obesity, and dysfunctions in vascular function,
and adipose development15,17,62–65. It is possible that these associated secondary effects of
in utero insults such as LBW, or maternal WD consumption on other organ systems can
eventually impact cardiac function, and lead to development of CVDs66,67. More
importantly, chronic postnatal exposure to WD is also associated with similar
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complications such as IR, and obesity, and can therefore enhance the deleterious effects of
in utero insults. We propose that given the shared consequences of in utero and postnatal
insults, the culmination of these complications would exacerbate and accelerate the
development of CVDs in adulthood. Lastly this study also demonstrated the significance
of non-invasive imaging on the early detection of markers of CVD development. The
ability to identify at risk individuals before the onset of severe complications is important
for the proposal of more effective treatment therapies. In summary the findings of this
study not only highlighted the risks of in utero and postnatal insults on CVD development,
but also opened new doors on the study of early diagnosis and intervention of the diseases
which increasingly plague our society.
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Appendix A. Primer sequences of selected target genes utilized in real-time PCR.

Gene
αSMA
Collagen
1
Collagen
3
MMP-2

Accession Number

F

R

ENSCPOT00000010480

AGCAAGAGAGGTATCCTGAC

CGCAGCTCATTGTAGAAAGT

XM_003466865.1

AACGGAGACACCTGGAAACC

TTGACTAGGTCCAGGGCTGA

XM_003478706.1

TGCTACTTTGAACCGCTTTT

TTCATCAACTTCCTGGGTCT

XM_003477541.1

CAGGGCACCTCCTACAACAG

CCTTCTGAGTTCCCACCGAC
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Appendix B. Ethics Approval

06.03.2010
*This is the Original Approval for this protocol*
*A Full Protocol submission will be required in 06.30.2014*
Your Animal Use Protocol form entitled:
In Utero Origins of Adult Insulin Resistance

Funding Agency CIHR - Grant #R3826A09
has been approved by the University Council on Animal Care. This approval is valid
from 06.03.2010 to 06.30.2011.
The protocol number for this project is 2010-229.
This number must be indicated when ordering animals for this project.
Animals for other projects may not be ordered under this number.
If no number appears please contact this office when grant approval is received.
If the application for funding is not successful and you wish to proceed with the
project, request that an internal scientific peer review be performed by the Animal Use
Subcommittee office.
Purchases of animals other than through this system must be cleared through the ACVS
office. Health certificates will be required.
ANIMALS APPROVED FOR 4 Years
Species

Strain

Other Detail

Pain
Level

Animal # Total
for 4 Years

Guinea Pig

Hartley

Pregnant ~25 Days on Arrival

C

556

The holder of this Animal Use Protocol is responsible to ensure that all associated safety components
(biosafety, radiation safety, general laboratory safety) comply with institutional safety standards and have
received all necessary approvals. Please consult directly with your institutional safety officers.
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Appendix C. ANOVA Table for Figure 2.3 Basal Coronary Blood Flow Determined
by DCE-CT.

Tests of Between-Subjects Effects
Dependent Variable: Blood Flow
Type III Sum
Source

of Squares

Partial Eta
df

Mean Square

F

Sig.

Squared

85632.376a

15

5708.825

1.064

.403

.166

3200825.235

1

3200825.235

596.304

.000

.882

Sex

2059.209

1

2059.209

.384

.537

.005

BirthType

1331.536

1

1331.536

.248

.620

.003

Diet

3436.354

1

3436.354

.640

.426

.008

Age

1162.622

1

1162.622

.217

.643

.003

408.484

1

408.484

.076

.783

.001

Sex * Diet

2191.975

1

2191.975

.408

.525

.005

Sex * Age

3066.114

1

3066.114

.571

.452

.007

BirthType * Diet

16410.451

1

16410.451

3.057

.084

.037

BirthType * Age

22302.282

1

22302.282

4.155

.045

.049

Diet * Age

2220.977

1

2220.977

.414

.522

.005

Sex * BirthType * Diet

4188.972

1

4188.972

.780

.380

.010

Sex * BirthType * Age

474.092

1

474.092

.088

.767

.001

5259.104

1

5259.104

.980

.325

.012

11771.423

1

11771.423

2.193

.143

.027

1536.422

1

1536.422

.286

.594

.004

Error

429421.793

80

5367.772

Total

4043459.083

96

515054.169

95

Corrected Model
Intercept

Sex * BirthType

Sex * Diet * Age
BirthType * Diet * Age
Sex * BirthType * Diet *
Age

Corrected Total

a. R Squared = .166 (Adjusted R Squared = .010)
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Appendix D. ANOVA Table for Figure 2.4 Cardiac Glucose Uptake by PET

Tests of Between-Subjects Effects
Dependent Variable: SUV
Type III
Sum of
Squares
17.612a

df
15

Mean Square
1.174

353.522
.235

1
1

.330
6.940

Age
Sex * BirthType

1.996

Sig.
.024

Partial Eta
Squared
.254

353.522
.235

600.876
.399

.000
.529

.872
.005

1
1

.330
6.940

.560
11.796

.456
.001

.006
.118

.557

1

.557

.947

.333

.011

.245

1

.245

.416

.520

.005

Sex * Diet

.249

1

.249

.423

.517

.005

Sex * Age

1.314

1

1.314

2.233

.139

.025

.991

1

.991

1.684

.198

.019

Source
Corrected Model
Intercept
Sex
BirthType
Diet

BirthType * Diet
BirthType * Age

F

.127

1

.127

.215

.644

.002

1.607

1

1.607

2.731

.102

.030

Sex * BirthType *
Diet
Sex * BirthType *
Age
Sex * Diet * Age

.878

1

.878

1.493

.225

.017

.230

1

.230

.391

.533

.004

.365

1

.365

.621

.433

.007

BirthType * Diet *
Age
Sex * BirthType *
Diet * Age

1.966

1

1.966

3.341

.071

.037

.930

1

.930

1.581

.212

.018

.588

Diet * Age

Error

51.774

88

Total

507.525

104

69.387

103

Corrected Total

a. R Squared = .254 (Adjusted R Squared = .127)
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Appendix E. ANOVA Table for Figure 2.5 Cross-Sectional Area of Cardiomyocytes

Tests of Between-Subjects Effects
Dependent Variable: Surface Area of Cardiomyocytes
Type III Sum of

Partial Eta

Source

Squares

Corrected Model

50224.931a

7

7174.990

3.027

.026

.527

2051230.300

1

2051230.300

865.426

.000

.979

Sex

4532.849

1

4532.849

1.912

.183

.091

BW

15683.581

1

15683.581

6.617

.019

.258

Diet

919.696

1

919.696

.388

.541

.020

Sex * BW

7925.713

1

7925.713

3.344

.083

.150

Sex * Diet

7416.964

1

7416.964

3.129

.093

.141

BW * Diet

1486.110

1

1486.110

.627

.438

.032

Sex * BW * Diet

3533.122

1

3533.122

1.491

.237

.073

Error

45033.740

19

2370.197

Total

2661565.249

27

95258.671

26

Intercept

Corrected Total

df

Mean Square

a. R Squared = .527 (Adjusted R Squared = .353)

F

Sig.

Squared
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Appendix F. ANOVA Table for Figure 2.6 Collagen Content in the Left Ventricle

Tests of Between-Subjects Effects
Dependent Variable: Fibrosis, Collagen percentage
Type III Sum
Source

of Squares

Partial Eta
df

Mean Square

F

Sig.

Squared

Corrected Model

34.094a

7

4.871

3.232

.021

.557

Intercept

141.860

1

141.860

94.126

.000

.839

Sex

1.695

1

1.695

1.124

.303

.059

BW

11.946

1

11.946

7.927

.011

.306

Diet

.848

1

.848

.563

.463

.030

Sex * BW

.020

1

.020

.014

.909

.001

Sex * Diet

7.469

1

7.469

4.956

.039

.216

BW * Diet

7.542

1

7.542

5.004

.038

.218

Sex * BW * Diet

19.298

1

19.298

12.805

.002

.416

Error

27.128

18

1.507

Total

202.192

26

61.222

25

Corrected Total

a. R Squared = .557 (Adjusted R Squared = .385)
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Appendix G. ANOVA Table for Figure 2.7 Type 1 Collagen mRNA Expression

Tests of Between-Subjects Effects
Dependent Variable: Collagen Type 1 mRNA
Type III Sum
Source

of Squares

Partial Eta
df

Mean Square

F

Sig.

Squared

Corrected Model

.128a

7

.018

3.020

.022

.490

Intercept

.681

1

.681

112.110

.000

.836

Sex

.069

1

.069

11.408

.003

.341

BW

.018

1

.018

3.041

.095

.121

Diet

.023

1

.023

3.774

.065

.146

Sex * BW

.031

1

.031

5.147

.033

.190

Sex * Diet

.001

1

.001

.178

.677

.008

BW * Diet

.005

1

.005

.784

.386

.034

3.715E-5

1

3.715E-5

.006

.938

.000

Error

.134

22

.006

Total

.934

30

Corrected Total

.262

29

Sex * BW * Diet

a. R Squared = .490 (Adjusted R Squared = .328)
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Appendix H. ANOVA Table for Figure 2.8 AKT Expression in the Left Ventricle at
Putdown.

Tests of Between-Subjects Effects
Dependent Variable: Ratio of pAKT (T308)
Type III Sum of
Source

Squares

Partial Eta
df

Mean Square

F

Sig.

Squared

Corrected Model

.009a

7

.001

2.580

.032

.368

Intercept

.195

1

.195

408.745

.000

.930

Sex

.003

1

.003

6.875

.013

.182

BW

.001

1

.001

2.745

.108

.081

Diet

.002

1

.002

5.060

.032

.140

Sex * BW

.000

1

.000

.303

.586

.010

Sex * Diet

.000

1

.000

.452

.506

.014

BW * Diet

.001

1

.001

1.784

.191

.054

Sex * BW * Diet

.001

1

.001

1.757

.195

.054

Error

.015

31

.000

Total

.216

39

Corrected Total

.023

38

a. R Squared = .368 (Adjusted R Squared = .225)
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Appendix I. ANOVA Table for Figure 3.5 A. Glucose Uptake Determined by PET

Tests of Between-Subjects Effects
Dependent Variable: SUV
Type III Sum
Source

of Squares

Partial Eta
df

Mean Square

F

Sig.

Squared

Corrected Model

2.581a

3

.860

1.654

.207

.191

Intercept

66.294

1

66.294

127.425

.000

.859

Pregnancy

.782

1

.782

1.503

.234

.067

Diet

.532

1

.532

1.022

.324

.046

2.129

1

2.129

4.092

.056

.163

Error

10.925

21

.520

Total

107.195

25

13.507

24

Pregnancy * Diet

Corrected Total

a. R Squared = .191 (Adjusted R Squared = .076)
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Appendix J. ANOVA Table for Figure 3.6 Protein Expression of pAKT (T308) at
Putdown.

Tests of Between-Subjects Effects
Dependent Variable: Ratio pAKT (T308)
Type III Sum
Source

of Squares

Partial Eta
df

Mean Square

F

Sig.

Squared

.055a

3

.018

3.548

.038

.400

1.282

1

1.282

249.749

.000

.940

Pregnancy

.010

1

.010

1.964

.180

.109

Diet

.035

1

.035

6.761

.019

.297

Pregnancy *

.003

1

.003

.601

.449

.036

Error

.082

16

.005

Total

1.530

20

.137

19

Corrected
Model
Intercept

Diet

Corrected Total

a. R Squared = .400 (Adjusted R Squared = .287)
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